Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 2914. Отображено 100.
01-03-2012 дата публикации

Adhesive structure with stiff protrusions on adhesive surface

Номер: US20120052234A1
Автор: Audrey Yoke Yee HO, Chee Tiong Lim, Hong Yee Low, Isabel Rodriguez, Kevin Cooper, Murty N. Vyakarnam, Noha ELMOUELHI, Sriram Natarajan
Принадлежит: Advanced Technologies and Regenerative Medicine LLC, Agency for Science Technology and Research Singapore

An adhesive structure is provided comprising a surface from which extend substantially cylindrical protrusions comprising a stiff resin having a Young's modulus of greater than 17 MPa. The protrusions are of sufficiently low diameter to promote adhesion by physical attractive forces, e.g., Van der Waals attractive forces, as measured by shear adhesion between the adhesive structure and a target surface. A method for preparing the structure is provided as well as a combination of the adhesive structure and target surface.

Подробнее
Номер записи: 1
05-04-2012 дата публикации

Apparatus and method for delivery of biological sealant

Номер: US20120083828A1
Автор: A. David Boccuti, Andrew Nicholas Gentile, Gary Whipple, J. Brent Ratz, John L. Wheeler, John Spiridigliozzi, Thomas T. Washburn
Принадлежит: Spinal Restoration Inc

A device for delivery of biologic materials, comprising: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams, as well as methods of making the device, methods of using the device to treat discs, kits including the device.

Подробнее
Номер записи: 2
25-10-2012 дата публикации

Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices

Номер: US20120270810A1
Автор: Guy Tomer, Orahn Preiss-Bloom
Принадлежит: Lifebond Ltd

Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Подробнее
Номер записи: 3
16-05-2013 дата публикации

Modified starch material of biocompatible hemostasis

Номер: US20130123213A1
Автор: CHENG Xing, Xin Ji, Xueshen Shi
Принадлежит: Individual

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Подробнее
Номер записи: 4
13-06-2013 дата публикации

Thrombin-free biological adhesive and use thereof as a medicament

Номер: US20130149292A1
Автор: Abdessatar Chtourou
Принадлежит: LFB SA

The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Подробнее
Номер записи: 5
11-07-2013 дата публикации

THERAPEUTIC AGENT FOR PULMONARY EMPHYSEMA

Номер: US20130178426A1
Автор: Anzai Takao, Nogawa Atsuhiko, Tada Yuichi
Принадлежит: TERUMO KABUSHIKI KAISHA

The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion. 1. A respiratory region volume inhibitor containing a coating film-forming component as a main component and capable of forming a coating film in a respiratory region ,being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g on each occasion.2. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component is configured such that a balloon-shaped closed pouch made of the coating film is formed in intimate contact with an inner surface of the respiratory region along an inner peripheral surface of the respiratory region in response to an external stimulation, andthe balloon-shaped closed pouch is shrunk by reducing a pressure inside the balloon-shaped closed pouch from outside of the respiratory region.3. The respiratory region volume inhibitor according to claim 2 ,wherein the external stimulation includes an external stimulation component.4. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains a tacky polymer, andthe external stimulation component is made of a reactive gas.5. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains polymer ...

Подробнее
Номер записи: 6
15-08-2013 дата публикации

Tissue Adhesive Film and Method for Producing Same

Номер: US20130211048A1
Автор: Taguchi Tetsushi
Принадлежит: NATIONAL INSTITUTE FOR MATERIALS SCIENCE

The present invention addresses the problem of providing: a tissue adhesive film having high adhesive strength and high biocompatibility; and a method for producing the tissue adhesive film. This problem can be solved by using a tissue adhesive film comprising an integration of gelatin and cross-linking reagents, wherein the gelatin is provided with an amino group on the side chain thereof and has a molecular weight of 50,000 or higher and 100,000 or lower, and the cross-linking reagents have two or more active ester groups or an anhydride.

Подробнее
Номер записи: 7
17-10-2013 дата публикации

COMPOSITIONS, THE PREPARATION AND USE THEREOF

Номер: US20130273145A1
Автор: Vail Neal
Принадлежит: KCI Licensing, Inc.

The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, biocompatiblility, and/or biodegradability. The compositions can have the ability of promoting cell attachment, cell adhesion, cell migration, cell differentiation, and/or morphogenesis. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body. 1. A composition for promoting cell interaction comprising a polycation and a polyanion , wherein at least one of the polycation and the polyanion comprises a peptide.2. (canceled)3. The composition of claim 1 , wherein the polycation comprises one or more amino groups.5. The composition of claim 1 , wherein at least one of the polycation and the polyanion comprises an engineered protein comprising a motif that promotes a cell interaction.6. (canceled)7. (canceled)8. (canceled)9. The composition of claim 5 , wherein the engineered protein comprises one or more sequences each independently selected from SEQ ID NO: 1 claim 5 , SEQ ID NO: 2 claim 5 , SEQ ID NO: 3 claim 5 , SEQ ID NO: 4 claim 5 , SEQ ID NO: 5 claim 5 , SEQ ID NO: 6 claim 5 , SEQ ID NO: 7 claim 5 , SEQ ID NO: 8 claim 5 , SEQ ID NO: 9 claim 5 , SEQ ID NO: 10 claim 5 , SEQ ID NO: 11 claim 5 , SEQ ID NO: 12 claim 5 , SEQ ID NO: 13 claim 5 , SEQ ID NO: 14. SEQ ID NO: 15 claim 5 , SEQ ID NO: 16 claim 5 , SEQ ID NO: 17 claim 5 , SEQ ID NO: 18 claim 5 , SEQ ID NO: 19 claim 5 , SEQ ID NO: 20 claim 5 , SEQ ID NO: 21 claim 5 , SEQ ID NO: 22 claim 5 , SEQ ID NO: 23 claim 5 , SEQ ID NO: 24. SEQ ID NO: 25 claim 5 , and SEQ ID NO: 26.10. (canceled)11. (canceled)12. The composition of claim 1 , ...

Подробнее
Номер записи: 8
13-02-2014 дата публикации

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

Номер: US20140041547A1
Автор: Ian J. Handley, Joanna Wang, Neil Winterbottom, Ronald Dieck
Принадлежит: Tenaxis Medical Inc

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Подробнее
Номер записи: 9
27-02-2014 дата публикации

RESTORATIVE MATERIALS

Номер: US20140053758A1
Автор: Booth Samantha, Nicholson John
Принадлежит: University of Greenwich

The present invention relates to restorative materials, in particular to glass-ionomer cements. More particularly, the present invention relates to glass-ionomer cements having particular utility in the repair of human hard tissue, in particular as dental restorative materials and in orthopaedic surgery. We describe a composition comprising a mixture of a glass ionomer cement and zinc phosphate. Preferably, the composition comprise from 40 to 95% by weight of glass ionomer cement and from to 60% by weight of zinc phosphate. The present invention also provides a powdered composition comprising a fluorosilicate glass and deactivated zinc oxide. Such that the zinc phosphate is formed in sith by reaction between the zinc oxide and phosphoric acid. 1. A composition comprising a mixture of a glass ionomer cement and zinc phosphate , wherein the zinc phosphate is prepared , in use , by reaction of zinc oxide and phosphoric acid; and wherein the glass ionomer cement is formed in use.2. A composition as claimed in comprising from 40 to 95% by weight of glass ionomer cement and from 5 to 60% by weight of zinc phosphate.3. A composition as claimed in comprising from 60 to 80% by weight of glass ionomer cement and from 20 to 40% by weight of zinc phosphate.4. A composition as claimed in comprising from 70 to 80% by weight of glass ionomer cement and from 20 to 30% by weight of zinc phosphate.5. A composition as claimed in comprising about 75% by weight of glass ionomer cement and about 25% by weight of zinc phosphate.6. A composition as claimed in claim wherein the glass ionomer cement is formed in situ by reaction of a precursor glass and a polyalkenoic acid.7. A composition obtainable by reacting together a glass ionomer cement precursor claim 1 , a polyalkeonoic acid claim 1 , zinc oxide and phosphoric acid.8. A precursor composition for the composition for claim 1 , the precursor composition comprising a mixture of fluorosilicate glass and deactivated zinc oxide.9. A ...

Подробнее
Номер записи: 10
07-01-2016 дата публикации

Hemostatic Compositions

Номер: US20160000962A1
Автор: Van Dongen Elisabeth Marianna Wilhelmina Maria
Принадлежит: FUJIFILM MANUFACTURING EUROPE B.V.

A cross linked recombinant gelatin composition for the induction of blood coagulation and hemostasis. 115.-. (canceled)16. A method for hemostatic treatment , comprising administering , to a patient with bleeding , a composition comprising a cross-linked gelatin with an isoelectric point of at least 7 , wherein the gelatin is a recombinant gelatin which is cross-linked using a carbodiimide and which comprises at least one RGD motif.17. The method according to wherein the gelatin prior to cross-linking has an isoelectric point of at least 7.18. The method according to wherein the gelatin prior to cross-linking has an isoelectric point of at least 9.19. The method according to wherein after cross-linking the cross-linked gelatin has an isoelectric point of at least 9.20. The method according to wherein the recombinant gelatin is free of hydroxyproline and hydroxylysine residues.21. The method according to wherein the recombinant gelatin comprises at least 0.40 mmol/g lysine residues before cross-linking.22. The method according to wherein the recombinant gelatin comprises a ratio between the total arginine and lysine amino acid residues and the total glutamine and asparagine amino acid residues that is at least 1.0.23. The method according to wherein the recombinant gelatin has a molecular weight of at least 50 kDa.24. The method according to wherein the gelatin is cross-linked using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC).25. The method according to wherein the recombinant gelatin is represented by CBE3. The present invention is directed to cross-linked gelatin compositions for medical use as a hemostatic agent. The present invention is further directed to the preparation of such compositions. These compositions are useful as hemostatic agents in a variety of medical applications, including vascular plug type devices, wound closure devices, dressings for use to treat incisions, seeping wounds, and the like.Hemostatic agents have a wide range ...

Подробнее
Номер записи: 11
04-01-2018 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20180000982A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

Подробнее
Номер записи: 12
04-01-2018 дата публикации

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

Номер: US20180000983A1
Автор: Brandacher Gerald, Brat Gabriel, Grahammer Johanna, Schneider Joel, SMITH Daniel
Принадлежит:

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Подробнее
Номер записи: 13
09-01-2020 дата публикации

LIQUID EMBOLIC AGENT COMPOSITION

Номер: US20200009290A1
Автор: NOMURA Takaomi, Ohkawa Kousaku, YUKI Ichiro
Принадлежит:

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

Подробнее
Номер записи: 14
03-02-2022 дата публикации

SELF-ASSEMBLING PEPTIDE COMPOSITIONS

Номер: US20220033442A1
Автор: Gil Eun Seok, Gilbert Karl, Mehta Manav
Принадлежит:

The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy). 1. An IEIK13 composition comprising:an IEIK13 peptide at a concentration of at least 0.25%;which composition has a pH within the range of about 2.5 to about 4.0.2. The composition of claim 1 , which composition is a solution.3. The composition of claim 1 , which composition is a gel.4. The composition of claim 1 , wherein the composition has ionic strength within the range of about 0.0001 M to about 0.1 M.5. The composition of claim 4 , wherein the ionic strength is adjusted/given by common salts claim 4 , wherein the common salts are selected from the group consisting of NaCl claim 4 , KCl claim 4 , MgCl claim 4 , CaCl claim 4 , and CaSO.6. The composition of claim 4 , wherein the ionic strength is given by common salts claim 4 , wherein the common salts are composed of one or more salt forming cations and one or more salt forming anions claim 4 , wherein the salt forming cations are selected from the group consisting of ammonium claim 4 , calcium claim 4 , iron claim 4 , magnesium claim 4 , potassium claim 4 , pyridinium claim 4 , quaternary ammonium claim 4 , and sodium claim 4 , wherein the salt forming anions are selected from the group consisting of acetate claim 4 , carbonate claim 4 , chloride ...

Подробнее
Номер записи: 15
21-01-2016 дата публикации

Spinal disk regenerative composition and method of manufacture and use

Номер: US20160015755A1
Автор: Harry Thomas Temple
Принадлежит: Vivex Biomedical Inc

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( 6 ) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material ( 10 ) that is dry and can be stored at room temperature for long periods of time. This powder ( 10 ) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture ( 20 ).

Подробнее
Номер записи: 16
21-01-2016 дата публикации

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Номер: US20160015855A1
Автор: Kobayashi Satoru, Matsuda Noriaki, Nohara Masahiro
Принадлежит: 3D-Matrix Ltd.

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

Подробнее
Номер записи: 17
17-01-2019 дата публикации

Dry Composition Comprising An Extrusion Enhancer

Номер: US20190015546A1
Автор: Larsen Kristian
Принадлежит:

Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes. 1. A dry composition suitable for use in haemostasis and wound healing comprising a frozen paste that has been freeze-dried , said dry composition comprising a biocompatible polymer , an extrusion enhancer and one or more polyols , wherein the dry composition is obtained by the method comprising sequentially:a) providing a cross-linked biocompatible polymer in powder form, one or more polyols selected from sugar alcohols or sugars, an extrusion enhancer and an aqueous medium;b) mixing the biocompatible polymer, the one or more polyols, the extrusion enhancer and the aqueous medium to obtain a paste; and 'wherein the dry composition comprises from about 10% w/w to about 60% w/w of the one or more polyols, and wherein upon addition of an aqueous medium, the dry composition reconstitutes to form a paste without mechanical mixing.', 'c) freeze-drying the paste,'}2. The dry composition according to claim 1 , wherein the extrusion enhancer is selected from albumin claim 1 , phosphatidylcholine claim 1 , phosphatidylserine claim 1 , lecithin or soy bean oil.3. The dry composition according to claim 1 , wherein the dry composition comprises from about 0.3% w/w to about 30% w/w of the extrusion enhancer.4. The dry composition according to claim 1 , wherein the biocompatible polymer is obtained from a cross-linked sponge.5. The dry composition according to claim 1 , wherein the biocompatible polymer is gelatine ...

Подробнее
Номер записи: 18
10-02-2022 дата публикации

Photoactivated crosslinking of a protein or peptide

Номер: US20220040371A1
Автор: Alan George Brownlee, Charles Mark Lindall, Christopher Malcolm Elvin, Jerome Anthony Werkmeister, John Alan Maurice Ramshaw
Принадлежит: Cook Medical Technologies LLC

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.

Подробнее
Номер записи: 19
24-01-2019 дата публикации

NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF

Номер: US20190023767A1
Автор: ABDILLAHI Suado, MÖRGELIN Matthias
Принадлежит:

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. 1. A polypeptide comprising or consisting of an amino acid sequence derived from collagen type VI , or a fragment , variant , fusion or derivative thereof , or a fusion of said fragment , variant of derivative thereof ,wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms.2. A polypeptide according to wherein the microorganisms are selected from the group consisting of bacteria claim 1 , mycoplasmas claim 1 , yeasts claim 1 , fungi and viruses.3. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of binding to the membrane of the microorganism.4. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of causing membrane disruption of the microorganisms.5. A polypeptide according to any one of the preceding claims which is capable of promoting wound closure.6. A polypeptide according to any one of the preceding claims claim 1 , wherein the polypeptide is capable of exhibiting an antimicrobial effect greater than or equal to that of LL-37.7. A polypeptide according to any one of ...

Подробнее
Номер записи: 20
28-01-2021 дата публикации

CEREBROSPINAL FLUID LEAKAGE OCCLUSION

Номер: US20210023257A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions. 1. (canceled)2. A method for treating cerebrospinal fluid leakage , the method comprising administering an effective amount of a self-assembling peptide solution to an area of dura associated with the cerebrospinal fluid leakage , wherein the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions;{'sup': 2', '2, 'wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof a site of the cerebrospinal fluid leakage; and'}the self-assembling peptide is about 0.1 to about 3.5 w/v % of the self-assembling peptide solution.3. The methods of claim 1 , wherein the target area comprises an area of dura associated with cerebrospinal fluid leakage.4. The method of claim 1 , wherein the hydrogel mitigates cerebrospinal fluid leakage.5. The method of claim 1 , wherein the hydrogel substantially prevents cerebrospinal fluid leakage.6. The method of claim 2 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and-a hydrophilic amino acids.7. The method of claim 2 , wherein the self-assembling peptide comprises a sequence selected from RADA (SEQ ID NO:1) claim 2 , IEIK (SEQ ID NO:2) claim 2 , TTTT (SEQ ID NO:3) claim 2 , ATAT (SEQ ID NO:4) claim 2 , TVTV (SEQ ID NO:5) claim 2 , ASAS (SEQ ID NO:6) claim 2 , SSSS (SEQ ID NO:7) claim 2 , VVVTTTT (SEQ ID NO:8) claim 2 , and a combination thereof.8. ...

Подробнее
Номер записи: 21
28-01-2021 дата публикации

Hydratable and flowable implantable compositions and methods of making and using them

Номер: US20210023258A1
Автор: Gretchen Selders, Ian Dunkley
Принадлежит: WARSAW ORTHOPEDIC INC

Implantable bone compositions are provided. The implantable compositions comprise hydratable bone putties. The hydratable bone putties comprise porous ceramic granules having an average diameter from about 50 μm to 800 μm. The porous ceramic granules comprise hydroxyapatite and beta-tricalcium phosphate. The implantable bone compositions further include collagen carriers. In some embodiments, the hydratable bone putty can be hydrated to form a non-settable flowable cohesive cement or gel. Methods of making and using the implantable compositions are also provided.

Подробнее
Номер записи: 22
04-02-2016 дата публикации

TREATMENT FOR BILE LEAKAGE

Номер: US20160030628A1
Автор: Kobayashi Satoru
Принадлежит: 3-D Matrix, Ltd.

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Подробнее
Номер записи: 23
04-02-2016 дата публикации

Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis

Номер: US20160030631A1
Автор: Anand K. AGARWAL, Boren Lin, Dong-Shik Kim, Sarit B. Bhaduri, Vijay K. Goel
Принадлежит: UNIVERSITY OF TOLEDO

Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described.

Подробнее
Номер записи: 24
04-02-2021 дата публикации

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

Номер: US20210030805A1
Автор: DU TOIT Donald, TURZI ANTOINE
Принадлежит:

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum sealed separator tube for preparing a therapeutic platelet concentrate from whole blood comprising:an inlet adapted to introduce whole blood;an anticoagulant composition comprising either: (i) a sodium citrate solution; or (ii) anhydrous sodium citrate; anda thixotropic gel selected from a polyester-based gel or a polymer mixture gel, the thixotropic gel being water insoluble and chemically inert to blood constituents;{'sup': '12', 'wherein the separator tube is adapted to be centrifuged when at least partially filled with the whole blood, at about 1,500 g up to about 2,000 g for about 3 to about 10 minutes in a single centrifugation to separate blood components in the whole blood into at least: (i) the therapeutic platelet concentrate obtained without supernatant removal and containing greater than 300 billion platelets per liter and less than about 0.6×10red blood cells per liter; and (ii) red blood cells.'}32. The separator tube according to claim 31 , wherein the anticoagulant composition comprises a 0.1 M sodium citrate solution.33. The separator tube according to claim 31 , wherein the anticoagulant composition comprises anhydrous sodium citrate.34. The separator tube according to claim 31 , wherein the thixotropic gel is a polyester-based gel.35. The separator tube according to claim 31 , wherein the separator tube is comprised at least of polyethylene terephthalate (PET).36. (canceled)37. ( ...

Подробнее
Номер записи: 25
04-02-2021 дата публикации

PRESSURE-SENSITIVE HYDROGEL AND METHOD OF USE

Номер: US20210030879A1
Автор: LIAO Chun Jen, WANG Wen Hsi, Wang Yu Ming
Принадлежит: TAIWAN BIOMATERIAL COMPANY LTD.

Embodiments of the disclosure may include a pressure sensitive hydrogel composition. The composition may include a liquid solvent, a polymer, and an acid gas. The composition may be capable of having a fluid phase in which the acid gas is dissolved in the solvent and the polymer is dissolved in the solvent, and the composition may be capable of having a gel phase in which the acid gas is not dissolved in the liquid solvent and the polymer is precipitated out of the solvent. The composition may also include a chemical compound or a pharmaceutical agent that can be released after the composition is delivered to a target tissue region. 1. A method of making a pressure-sensitive hydrogel composition , comprising:exposing a polymer and a solvent to an acid gas; andsubjecting the polymer, the solvent, and the acid gas to an increase in pressure to dissolve the acid gas in the solvent to form an acidic solution, causing the polymer to dissolve into the solution to form a fluid under a first pH,subjecting the fluid to a decrease in pressure causes the acid gas to come out of solution to form a gel under a second pH higher than the first pH,wherein the fluid and the gel are reversibly interchangeable.2. The method of claim 1 , wherein the polymer is selected from the group consisting of collagen claim 1 , gelatin claim 1 , cellulose claim 1 , hyaluronic acid claim 1 , casein claim 1 , alginate claim 1 , fibrinogen claim 1 , thrombin claim 1 , and any combination thereof.3. A method of repairing tissue claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'delivering and pressurizing the pressure-sensitive hydrogel composition of to a target tissue region; and'} wherein the hydrogel composition comprises the polymer, the solvent and the acid gas,', 'wherein the pressurized hydrogel composition is in a liquid state, and', 'wherein the depressurized hydrogel composition is in a gel state., 'depressurizing the hydrogel composition,'}4. The method of claim 3 , ...

Подробнее
Номер записи: 26
04-02-2021 дата публикации

GLASS COMPOSITION AND GLASS POWDER, IN PARTICULAR FOR THE USE IN THE DENTAL FIELD

Номер: US20210032154A1
Автор: Pichler-Wilhelm Sabine, Ritter Simone Monika, Suffner Jens
Принадлежит:

The present disclosure relates to a glass composition as well as a glass powder. The disclosure also relates to the use in the dental field, e.g. as dental material such as dental filling or dental restauration material, in particular as or for the production of a glass ionomer cement, for example for the treatment and/or for the filling of cavities in human and/or animal teeth and/or for tooth restoration. 5. The glass according to claim 1 , wherein the component 1 comprises SiOand POand wherein the component 2 comprises AlO.7. The glass according to claim 1 , wherein the ratio of the proportion by weight of AlOto the proportion by weight of SiOis in a range of 0.9:1 to 1.15:1.8. The glass according to claim 1 , wherein the glass contains at least one X-ray absorbing component selected from the group consisting of YO claim 1 , YbO claim 1 , LaO claim 1 , SrO claim 1 , BaO and CsO in a proportion of in total at least 0.1% by weight.9. The glass according to claim 1 , wherein the ratio of the proportion by weight of the component 2 to the proportion by weight of the component 1 is in a range of 1.0:1 to 1.6:1.10. The glass according to claim 1 , wherein the ratio of the proportion by weight of the component 2 to the proportion by weight of the component 3 is in a range of 1.0:1 to 6.5:1.11. The glass according to claim 1 , wherein the ratio of the proportion by weight of the component 1 to the proportion by weight of the component 3 is in a range of 0.8:1 to 4.5:1.12. The glass according to claim 1 , wherein the glass has a refractive index of from 1.43 to 1.55.13. A glass powder comprising particles of glass powder claim 1 , wherein the particles of glass powder comprise the glass according to claim 1 , and wherein the particle size of the glass powder claim 1 , when specified as d50 value claim 1 , is in a range of 0.2 μm to 20 μm.14. A method of making a glass ionomer cement claim 1 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'mixing ...

Подробнее
Номер записи: 27
05-02-2015 дата публикации

Dry Haemostatic Composition

Номер: US20150037314A1
Автор: Larsen Kristian
Принадлежит:

Disclosed is a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. Further disclosed are methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. 2. The method according to claim 1 , wherein the paste prior to drying comprises from 3% w/w to 20% w/w of one or more polyols.3. The method according to claim 1 , wherein the biocompatible polymer is gelatine.4. The method according to claim 3 , wherein the gelatine is obtained from a cross-linked gelatine sponge.5. The method according to claim 1 , wherein the paste prior to freeze-drying comprises:a) from 5% w/w to 20% w/w of one or more polyols;b) from 15% w/w to 25% w/w of biocompatible polymer; andc) from 60% w/w to 80% w/w of water.6. The method according to claim 1 , wherein the dry composition comprises less than 5% w/w of water.7. The method according to claim 1 , wherein the one or more polyols is selected from sugar alcohols and sugars.8. The method according to claim 7 , wherein the one or more sugar alcohols is selected from glycol claim 7 , glycerol claim 7 , erythritol claim 7 , threitol claim 7 , arabitol claim 7 , xylitol claim 7 , ribitol claim 7 , mannitol claim 7 , sorbitol claim 7 , dulcitol claim 7 , fucitol claim 7 , iditol claim 7 , inositol claim 7 , volemitol claim 7 , isomalt claim 7 , maltitol claim 7 , lactitol or polyglycitol.9. The method according to claim 1 , wherein the one or more polyols is mannitol.10. The method according to claim 9 , where the dry composition comprises one or more further polyols.11. The method according to claim 1 , wherein the dry composition further comprises one or more bioactive agents that stimulate haemostasis or wound claim 1 , bone claim 1 , tendon and/or tissue healing. ...

Подробнее
Номер записи: 28
05-02-2015 дата публикации

Compositions, the Preparation and Use Thereof

Номер: US20150038400A1
Автор: Vail Neal
Принадлежит: KCI Licensing, Inc.

The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, biocompatiblility, and/or biodegradability. The compositions can have the ability of promoting cell attachment, cell adhesion, cell migration, cell differentiation, and/or morphogenesis. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body. 1102-. (canceled)103. A kit comprising a polycation and a polyanion , wherein the polycation comprises an engineered protein and the polyanion comprises a glycosaminoglycan.104. The kit of claim 103 , wherein the engineered protein is a recombinant protein.105. The kit of claim 103 , wherein the engineered protein comprises one or more crosslinkable groups.106. The kit of claim 105 , wherein the one or more crosslinkable groups comprises an ortho-dihydroxy aromatic group.107. The kit of claim 106 , wherein the ortho-dihydroxy aromatic group is a DOPA residue.108. The kit of claim 103 , wherein the glycosaminoglycan is hyaluronic acid.109. The kit of claim 103 , wherein the polycation comprises a recombinant protein comprising one or more DOPA residues and the polyanion comprises hyaluronic acid.110. An adhesive complex coacervate comprising a polycation and a polyanion claim 103 , wherein the polycation comprises an engineered protein and the polyanion comprises a glycosaminoglycan.111. The adhesive complex coacervate of claim 110 , wherein the engineered protein is a recombinant protein.112. The adhesive complex coacervate of claim 110 , wherein the engineered protein comprises one or more crosslinkable groups.113. The adhesive complex ...

Подробнее
Номер записи: 29
11-02-2016 дата публикации

COMPOSITIONS HAVING CYLINDRICAL VOLUME, METHODS, AND APPLICATORS FOR SEALING INJURIES

Номер: US20160038347A1
Автор: BEALL Dawson, BRICHETTI Jennifer, MACPHEE Martin, WILMER Belinda
Принадлежит:

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A haemostatic material for treating wounded internal tissue in a mammal comprising a cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator wherein said cylindrical haemostaic material is made by combining liquid fibrinogen and liquid fibrinogen at about 12° C. to 0° C. and preferable between 4° C.+/−2° C. into a cylindrical mold , freezing and thereafter lyophilizing said material , wherein said fibrinogen component is present in an amount between 1 mg/cmand 75 mg/cmand said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to reduce the flow of fluid from said wounded tissue and/or join or approximate said wounded tissue , wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator , wherein said fibrinogen component is present in an amount between 1 mg/ml and 37.5 mg/ml and said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized. ...

Подробнее
Номер записи: 30
05-02-2015 дата публикации

FORMULATIONS AND KITS FOR FORMING BIOADHESIVE MATRICES

Номер: US20150038424A1
Автор: Cohen Binyamin, Foox Maytal, Shefy-Peleg Adaya, ZILBERMAN Meital
Принадлежит:

A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed. 1. A bioadhesive formulation comprising:a) gelatin;b) alginate;c) a coupling agent; andd) water,wherein a concentration of said gelatin in the formulation is less than 500 mg/ml,the formulation being characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec.2. The bioadhesive formulation of claim 1 , being for forming a bioadhesive matrix upon curing claim 1 , wherein a curing time for forming said matrix ranges from 5 seconds to 30 minutes.3. The formulation of claim 2 , being such that said matrix is characterized by at least one of:a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; anda biodegradability rate that ranges from 7 days to 6 months.4. The formulation of claim 1 , wherein a concentration of said gelatin in the formulation ranges from 100 mg/ml to 300 mg/ml.5. The formulation of claim 1 , wherein a concentration of said alginate in the formulation ranges from 10 mg/ml to 60 mg/ml.6. (canceled)7. The formulation of claim 1 , wherein a concentration of said gelatin ranges from 200 mg/ml to 300 mg/ml claim 1 , a concentration of said alginate ranges from 20 mg/ml to 40 mg/ml and a concentration of said coupling agent ranges from 10 mg/ml to 30 mg/ml.8. The formulation of claim 1 , ...

Подробнее
Номер записи: 31
09-02-2017 дата публикации

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

Номер: US20170035861A1
Автор: Garner John, Phillips Victor Matthew
Принадлежит:

A flowable hemostatic gel composition is provided for use at a site of a defect within a biological tissue. The flowable hemostatic gel composition includes a flowable gel solution that includes a biopolymer dissolved in a first solvent. The biopolymer is configured to cross-link with red blood cells at the site to facilitate clot formation at the site. The flowable hemostatic gel composition also includes at least one additional active agent. 1. A method of inhibiting bleeding from a site of a defect within a biological tissue , said method comprising applying a flowable hemostatic gel composition to the site such that a biopolymer of the flowable hemostatic gel composition cross-links with red blood cells at the site to facilitate clot formation at the site , the flowable hemostatic gel composition including:a flowable gel solution that includes the biopolymer dissolved in a first solvent, andat least one additional active agent.2. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of a lumen of an injection device.3. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises applying the biopolymer that is substantially polycationic dissolved in the first solvent that is a dilute acid.4. The method of claim 3 , wherein said applying the flowable hemostatic gel composition comprises applying the biopolymer that includes chitosan dissolved in the first solvent that includes lactic acid.5. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises applying the at least one additional active agent that includes at least one clotting agent.6. The method of claim 5 , wherein said applying the flowable hemostatic gel composition comprises applying the at least one clotting agent that is at least one of thrombin and fibrinogen.7. The method of claim 6 , wherein said applying the flowable hemostatic gel ...

Подробнее
Номер записи: 32
09-02-2017 дата публикации

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

Номер: US20170035929A1
Автор: Garner John, Phillips Victor Matthew
Принадлежит:

A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site. 1. A method of inhibiting bleeding from an open surgical site , said method comprising:mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition; andapplying the flowable hemostatic gel composition to the open surgical site, wherein the cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.2. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution within a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.3. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution prior to introducing the flowable hemostatic gel composition into a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.4. The method of claim 1 , wherein said mixing the flowable gel solution ...

Подробнее
Номер записи: 33
08-02-2018 дата публикации

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

Номер: US20180036346A1
Автор: DU TOIT DONALD FRANCOIS, TURZI ANTOINE
Принадлежит:

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A method of treating a patient with platelet rich plasma , the method comprising:withdrawing blood from the patient;centrifuging the blood in a centrifugation tube containing a thixotropic gel and an anticoagulant, the thixotropic gel being configured to separate platelet rich plasma, the centrifuging being performed for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;removing the platelet rich plasma from the tube; andadministering the platelet rich plasma to the patient.2. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force between about 1500 g and about 2000 g for about 3 to 10 minutes.3. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force of at least 1500 g for at least 8 minutes.4. The method of claim 1 , further comprising separating the platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.5. The method of claim 4 , further comprising re-suspending the platelet rich plasma in the tube claim 4 , wherein said re-suspending follows said separating the platelet rich plasma.6. The method of claim 1 , further comprising admixing the platelet rich plasma with a coagulation activator claim 1 , wherein the coagulation activator comprises at least one of: a thrombin activator claim 1 , a fibrinogen activator claim 1 , a calcium claim 1 , a calcium salt claim 1 , a CaCl ...

Подробнее
Номер записи: 34
24-02-2022 дата публикации

Liquid medical material

Номер: US20220054701A1
Автор: Hironori Arima, Hirotsugu Kido, Katsunori Chiba, Kenji Ohata
Принадлежит: AOBAKASEI KK, Osaka City University In University Public Corp Osaka

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

Подробнее
Номер записи: 35
06-02-2020 дата публикации

Fibrinogen composition, method and wound articles

Номер: US20200038546A1
Автор: Amy S. Determan, James P. DiZio, Jason W. Bjork, Jonathan J. O'hare, Robert A. Asmus, Zhicheng TIAN
Принадлежит: 3M Innovative Properties Co

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

Подробнее
Номер записи: 36
18-02-2021 дата публикации

APPARATUS AND METHOD OF USING IN SITU SOLIDIFYING COMPLEX COACERVATES FOR VASCULAR OCCLUSION

Номер: US20210045748A1
Автор: FOJTIK Shawn Patrick, Stewart Russell
Принадлежит:

Described herein are the use of fluid complex coacervates that produce solid adhesives in situ to anchor medical devices such as catheters in a blood vessel. The anchored devices permit the targeted delivery of bioactive agents. The anchored devices can perform as an embolic agent by reducing or preventing blood flow in the vessel. Additionally, the embolic produced from the solid adhesive produced in situ can also include one or more bioactive agents that can be released in a controlled manner. 1. A method for anchoring a catheter in a blood vessel of a subject , the method comprising(a) inserting into a blood vessel of a subject a first catheter and a second catheter, wherein the second catheter is extended further into the vessel than the first catheter; and(b) injecting into the first catheter an in situ solidifying complex coacervate to produce an adhesive in the vessel that adheres the second catheter to the inner wall of the vessel, wherein the in situ solidifying complex coacervate comprises at least one polycation, at least one polyanion, and a salt that produces ions in water, wherein the concentration of the ions in the complex coacervate is greater than the concentration of the ions in the blood vessel.2. The method of claim 1 , wherein the first catheter and second catheter are a co-axial catheter.3. The method of claim 1 , wherein the second catheter comprises an occlusion balloon catheter.4. The method of claim 1 , wherein the first catheter and second catheter are sistered to one another.5. The method of claim 4 , wherein the diameter of the first catheter is greater than the diameter of the second catheter.6. The method of claim 5 , wherein the tip of the second catheter extends past the tip of the first catheter.7. The method of claim 1 , wherein the adhesive completely seals the vessel.8. The method of claim 1 , wherein the first catheter is removed from the vessel.9. The method of claim 1 , wherein the second catheter is removed and the resulting ...

Подробнее
Номер записи: 37
18-02-2016 дата публикации

Partially-denatured protein hydrogels

Номер: US20160045606A1
Автор: Guillermo A. Ameer, Igal G. Szleifer, Kevin Baler
Принадлежит: Northwestern University

Provided herein are partially-denatured protein (e.g., albumin) hydrogels and methods of manufacture (e.g., pH induction) and use (e.g., drug delivery) thereof.

Подробнее
Номер записи: 38
15-02-2018 дата публикации

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

Номер: US20180042964A1
Автор: DU TOIT DONALD FRANCOIS, TURZI ANTOINE
Принадлежит:

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A medical separator system for preparation of a platelet concentrate , comprising: a thixotropic gel being adapted to separate blood components in whole blood to provide a platelet concentrate containing less than or equal to 1% hematocrit and a pellet containing more than or equal to 99% hematocrit by forming a barrier between plasma and erythrocytes when said tube is centrifuged; and', 'an anticoagulant being adapted to at least reduce coagulation of said whole blood., 'a tube being adapted to be centrifuged for a length of time and containing two additives, wherein said two additives include2. The medical separator system of claim 1 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate containing 2 or more times a normal level of platelets and growth factors compared to said whole blood.3. The medical separator system of claim 2 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate with platelet recovery of 95%±5%.4. The medical separator system of claim 3 , wherein no other additives are contained in said tube.5. A kit comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'a medical separator system of ; and'}an applicator device for applying said platelet concentrate to a patient for medical, therapeutic, or skincare application.6. The medical separator system of claim 3 , ...

Подробнее
Номер записи: 39
15-02-2018 дата публикации

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

Номер: US20180043053A1
Автор: KHANDAKER Morshed, RIAHINEZHAD Shahram
Принадлежит:

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 1. A process providing a method to enhance mechanical stability and osseointegration of PolyMethylMethAcrylate (PMMA) cement with bone in surgeries using a metallic implant , comprising:amending surface areas of said implant using at least one of grooves or ion deposition;mixing nanoparticles as additives with PMMA cement;immobilizing osteoconductive nanomaterials with electrospun nanofibers (ENF), andconstruction of a membrane using said ENF said membrane exhibiting adequate stiffness to control the movement of said cement into said bone,wherein said nanofiber membrane is inserted into a formed cavity in said bone, said PMMA cement is deposited into said nanofiber membrane, and said implant is inserted into said formed cavity.2. The process of claim 1 , wherein microgroves on said implant are coupled with growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).3. The process of claim 1 , wherein fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM coating are coupled on said implant.4. The process of claim 1 , further comprising immobilizing cell adhesion matrix protein (collagen claim 1 , fibronectin) and bone growth molecules (rhBMP claim 1 , TGF-β) using said ENF membrane to increase ...

Подробнее
Номер записи: 40
15-02-2018 дата публикации

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

Номер: US20180043054A1
Автор: Chen Shuang, Feng Dengmin, Li Yufu, Wan Xiang
Принадлежит:

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; andthus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether CFOCH.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in ...

Подробнее
Номер записи: 41
15-02-2018 дата публикации

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

Номер: US20180043055A1
Автор: BAKER BRYAN A., BEEN RAHA A., Bjork Jason W., NINKOVIC Jana, Young Alexi J
Принадлежит:

A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces. Also described are methods of forming a fibrin article, wound dressings and a method of treatment of a wound. 1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.2. The method of wherein the fibrin hydrogel forming salt comprises calcium salt.3. The method of wherein the threshold concentration of the aqueous solution is at least 0.45 wt %.4. The method of wherein the aqueous solution further comprises a plasticizer.5. The method of wherein the plasticizer comprises a sugar alcohol claim 4 , an alkane diol claim 4 , or a combination thereof.6. The method of wherein the solution further comprises a buffering agent.7. The method of further comprising forming the fibrin hydrogel into a sheet claim 1 , foam ...

Подробнее
Номер записи: 42
03-03-2022 дата публикации

Hemostatic Composition And Preparation Method Therefor

Номер: US20220062496A1
Автор: Chen Hao, FAN Jie, Shang Xiaoqiang, Xiao Liping, Yu Lisha
Принадлежит:

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

Подробнее
Номер записи: 43
19-02-2015 дата публикации

METHODS OF BREAST SURGERY

Номер: US20150051623A1
Автор: Bowley Melissa
Принадлежит: C.R. BARD, INC.

Surgical procedures of the breast where an adhesive is applied to fixate a reshaped and/or relocated portion of breast tissue. 1. A method of treating breast tissue , comprising:moving a first portion of breast tissue from a first location to a second location; andapplying an adhesive to retain the first portion of breast tissue at the second location.2. The method of claim 1 , wherein the adhesive is applied to the first portion of breast tissue.3. The method of claim 1 , wherein the adhesive is applied to an anatomical structure at the second location.4. The method of claim 3 , wherein the adhesive is applied to the anatomical structure before the first portion of breast tissue is moved to the second location.5. The method of claim 4 , further comprising contacting the first portion of breast tissue with the anatomical structure.6. The method of claim 2 , wherein the anatomical structure comprises at least one of skin overlying breast tissue claim 2 , breast tissue claim 2 , chest wall claim 2 , periosteum or skin at an upper pole portion of a breast.7. (canceled)8. The method of claim 2 , wherein the adhesive is applied to the first portion of breast tissue after the first portion of breast tissue is moved to the second location.9. The method of claim 1 , wherein the adhesive is applied to a prosthetic.10. The method of claim 9 , wherein the prosthetic is selected from the group consisting of a surgical repair fabric and a breast implant.11. (canceled)12. The method of claim 1 , wherein the second location is anatomically superior to the first location.13. The method of claim 1 , further comprising moving a second portion of breast tissue from a third location to a fourth location; andapplying an adhesive to retain the second portion of breast tissue at the fourth location.14. The method of claim 13 , wherein the second portion of breast tissue is placed adjacent to the first portion of breast tissue.15. The method of claim 14 , further comprising applying an ...

Подробнее
Номер записи: 44
25-02-2016 дата публикации

Implant and insertion device for an implant

Номер: US20160051194A1
Автор: Michael Diebold, Thomas Doerr
Принадлежит: Biotronik SE and Co KG

Embodiments include an implant for insertion into a human and/or animal body and an insertion device for the implant. The implant includes a housing, at least one negative pressure unit and at least one adhesive application unit to temporarily and/or permanently fix the implant to a bodily tissue.

Подробнее
Номер записи: 45
22-02-2018 дата публикации

Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients

Номер: US20180050127A1
Автор: REFAAI Majed A.
Принадлежит:

The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same. 1. A blood clotting composition comprising:isolated platelet microparticles; one or more factors selected from fibrinogen (Factor I), von Willebrand factor, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Protein C (PC), Protein S (PS), antithrombin III (ATIII); and a pharmaceutical carrier;wherein fibrinogen is at about 10-1000 mg/deciliter (dL), Factor V is at about 0.5-2.0 International Unit (IU), Factor VII is at about 0.5-4.0 IU, Factor VIII is at about 0.2-2.0 IU, Factor IX is at about 0.5-3.0 IU, Factor XI is about 0.5-3.0 IU, Factor XII is at about 1.0-7.0 IU, Protein C (PC) is at about 25-300% activity, Protein S (PS) is at about 10-150% activity, antithrombin III (ATIII) is about 25-250% activity.2. The composition of claim 1 , wherein the composition has either prothrombin time that is within a normal reference range or an activated partial thromboplastin time that is within a normal reference range.3. (canceled)4. The composition of claim 1 , wherein the composition has a blood clot initiation time (R-time) of less than three minutes when measured using thromboelastography.5. The composition of claim 1 , wherein the concentration of platelet microparticles in the composition is >10″ microparticles/μl.6. The composition of claim 1 , wherein the composition comprises two or more of the factors or all eight factors.7. (canceled)8. The composition of claim 1 , wherein the composition is formulated for topical administration or systemic administration.9. The composition of claim 8 , wherein the composition is formulated as a spray claim 8 , powder claim 8 , cream claim 8 , gel claim 8 , or ointment.10. (canceled)11. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the blood clotting composition of and'}a wound dressing ...

Подробнее
Номер записи: 46
01-03-2018 дата публикации

Three Dimensional Healing Kit

Номер: US20180055912A1
Автор: AKMAN Serhan, TUNALI Mustafa
Принадлежит:

Invention; is about the kit that enables three-dimensional healing with the platelet-rich fibrin framework support used in hard and soft tissue healing. 1111122. It is the three-dimensional healing kit , and characterized by a network structured apparatus (.) , fibrin generation apparatus () containing the carrier rod (.) and fibrin compression apparatus ().22212223. It is the fibrin compression apparatus () mentioned in claim 1 , and characterized by a piston (.) claim 1 , a container (.) the carrier rod centralizer (.).311. It is the network structured apparatus (.) mentioned in claim 1 , and characterized by comprising at least one layer.411. It is the network structured apparatus (.) mentioned in claim 1 , and characterized by the fact that it comprises pores thorough which all elements of the blood can pass during centrifugation.511. It is the network structured apparatus (.) mentioned in claim 1 , and characterized by the fact that it contains the agents (calcium phosphate compounds claim 1 , titanium claim 1 , collagen claim 1 , Bioceramics and resorbable polymers) that accelerate the formation of fibrin.611. It is the network structured apparatus (.) mentioned in claim 1 , and characterized by the fact that it has a structure that can be shaped in accordance with the surface where it will be applied.722221. It is the container ( claim 2 ,) mentioned in claim 2 , and characterized by a removable bottom base (..) it has.822. It is the container ( claim 2 ,) mentioned in claim 2 , and characterized by having different geometric shapes.921. It is the piston (.) mentioned in claim 2 , and characterized by being different geometric shapes that can give suitable form to the surface where fibrin will be placed.10. It is the layer mentioned in and it is characterized by being a part that accelerates and enhances organic and inorganic fibrin formation suitable to the tissue to be applied claim 3 , and enhances the auxiliary wound healing agents (implants claim 3 , ...

Подробнее
Номер записи: 47
04-03-2021 дата публикации

METHOD FOR TREATING ACTIVE BLEEDING USING BIOCOMPATIBLE HEMOSTATIC AND SEALANT COMPOSITIONS

Номер: US20210060204A1
Автор: Ji Xin, Shi Xueshen, Zhang Xiaoguang
Принадлежит:

The present specification describes a biocompatible hemostatic composition and a biocompatible tissue sealant, which when used in combination provides a safe and effective method of achieving hemostasis. The biocompatible composition and sealant may be applied either on a surface of the patient's body, or inside the body cavity. The combination may be used to control bleeding from external wounds and internal injuries, as well as to minimize bleeding during surgical procedures. 1. A method of using a combination of a biocompatible hemostatic product and a biocompatible sealant product to treat a bleeding wound within or on a mammal , comprising:applying a first amount of said biocompatible hemostatic product to said bleeding wound; and,applying a second amount of said biocompatible sealant product to the bleeding wound, wherein said first amount and said second amount in combination are sufficient to cause at least one of: hemostasis in said bleeding wound, wound sealing in said wound, reducing exudation of said bleeding wound, promoting tissue healing of said wound, protecting a surface of said wound, and avoiding infection of said wound.2. The method of claim 1 , wherein said biocompatible hemostatic product comprises at least one of a biocompatible hydrophilic hemostatic modified starch claim 1 , cellulose claim 1 , cellulose derivatives claim 1 , chitosan claim 1 , chitosan derivatives claim 1 , alginate and alginate derivatives.3. The method of claim 1 , wherein said biocompatible sealant product comprises at least one of:at least one of a biocompatible modified starch gel, a polysaccharide glue, a fibrin glue, a thrombin glue, and a bioglue; andat least one sugar selected from polysaccharides, oligosaccharides and oligosaccharides, such as Pullulan polysaccharide, maltose, pre-gelatinized starch, Dextran, hydroxypropyl distarch phosphate, sodium carboxymethyl starch, crosslinked carboxymethyl starch, hydroxyethyl starch, oxidized starch, and grafted starch.4. ...

Подробнее
Номер записи: 48
28-02-2019 дата публикации

TISSUE PATCH

Номер: US20190060510A1
Автор: Ericson Daniel Grant
Принадлежит: Xcede Technologies, Inc.

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. For example, in some embodiments, tissue patches are made by applying a compressive force to a liquid medium comprising fibrinogen (and/or fibrin) between two surfaces (e.g., within a syringe or other chamber). A filter can be placed within or near the volume in which the compressive force is applied to the liquid medium such that unwanted material (e.g., water, blood cells, and the like) is passed through the filter while desirable components (e.g., fibrin, fibrinogen, and/or other desirable components) are retained by the filter to form the patch. In this way, the concentration of fibrin (and/or fibrinogen) within the liquid medium can be increased, potentially dramatically, as the compressive force is applied to the liquid-containing composition. In addition, in some embodiments, at least a portion of the fibrinogen and/or fibrin can chemically react (e.g., the fibrinogen can polymerize to form fibrin and/or the fibrin can cross-link) during application of the compressive force. Reaction and concentration can lead to the formation of a highly-concentrated, mechanically robust patch that can be handled relatively easily and provide good structural reinforcement at a wet site, such as a bleeding wound. 1. (canceled)2. A patch , comprising:a primer region comprising a water-activated polymeric adhesive; anda solid matrix positioned over at least a portion of the primer region, the water-activated polymeric adhesive comprises one or more polymers of acrylic acid cross-linked with a polyalkenyl ether and/or a divinyl alcohol; and', 'the patch is configured for application to a tissue surface., 'wherein3. The patch of claim 2 , wherein the solid matrix comprises fibrin.4. The patch of claim 2 , wherein the solid ...

Подробнее
Номер записи: 49
12-03-2015 дата публикации

Haemostatic wound dressing

Номер: US20150071985A1
Автор: Greg Walker, Sarah Margaret Middleton
Принадлежит: Haemostatix Ltd

Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.

Подробнее
Номер записи: 50
15-03-2018 дата публикации

SEALANT FORMULATIONS AND USES THEREOF

Номер: US20180071429A1
Автор: Eavri Ronen, Gantz Amatzia, Mintz Roni, Nur Israel, VISNOVEZKY Damian
Принадлежит:

The invention relates to a storage-stable aqueous sealant formulation comprising a blood derived fibrinogen concentrate, a divalent cation and factor XIa. 1. A storage-stable aqueous sealant formulation comprising a blood derived fibrinogen concentrate , a divalent cation and factor XIa , the sealant formulation is stable at a temperature of between 20° C.-25° C. for at least 5 minutes.2. The sealant formulation of claim 1 , wherein said divalent cation is a calcium cation optionally claim 1 , provided by calcium chloride optionally claim 1 , in an amount of between 0.15 to 0.5 mg/ml.3. The sealant formulation of claim 1 , comprising fibronectin at a relative concentration of fibronectin:fibrinogen of more than 0.078 such as at a relative concentration of fibronectin: fibrinogen of between 0.1 to 0.2.4. The sealant formulation of claim 1 , comprising clottable proteins in an amount that is lower than 79.8% out of the total amount of proteins in said formulation claim 1 , the total amount excludes said factor XIa.5. The sealant formulation of claim 1 , that is in liquid form.6. The sealant formulation of claim 1 , that is in solid frozen form.7. The sealant formulation of claim 1 , wherein said fibrinogen is in an amount of between 13 to 85 mg/ml such as 13 to 29 mg/ml.8. The sealant formulation of claim 1 , wherein said factor XIa is in an amount of between 0.01 to 110 g/ml claim 1 , such as an amount of between 0.11 to 110 g/ml claim 1 , ans such as an amount higher than 0.11 and up to 110 μg/ml.9. The sealant formulation of claim 1 , that is free of thrombin.10. The sealant formulation of claim 1 , that is stable at a temperature of between 2° C.-8° C. for at least two weeks.11. The sealant formulation of claim 1 , that is stable at a temperature of −30° C. for at least 15 months.12. The sealant formulation of claim 1 , that is free of vitamin K dependent clotting zymogens.13. An applicator comprising (i) a container holding a sealant formulation comprising a ...

Подробнее
Номер записи: 51
24-03-2022 дата публикации

BIOMATERIALS AND METHODS RELATED THERETO

Номер: US20220088265A1
Автор: DOMIGAN Laura Joy, GLASSON Judith Louise, KAUR Manmeet, SAMARASEKARA Kishara, SHERWIN Trevor
Принадлежит:

The present invention relates to biocompatible compositions comprising one or more crystallin proteins, and the use of such compositions in therapeutic and research methods, for example in surgical methods, in sustained release drug delivery, and in cell-based methods. 1. A biocompatible composition comprising:{'claim-text': ['a. an α-crystallin;', 'b. a β-crystallin;', 'c. a γ-crystallin;', {'i': 'Macruronus novaezelandiae', '#text': 'd. a protein from any one of a) to c) above from Hoki ();'}, {'i': 'Homo sapiens;', '#text': 'e. a protein from any one of a) to c) above from'}, 'f. a protein comprising the amino acid sequence identified in Table 1 herein;', 'g. a polypeptide comprising or consisting of at least about 10 contiguous amino acids from any one of a) to f) above;', 'h. a protein having at least about 90% amino acid identity to any one of a) to g) above;', 'i. a protein according to any one of a) to h) above having the native structure of a crystallin protein in vivo;', 'j. any combination of two or more of a) to i) above;'], '#text': 'one or more isolated, purified, recombinant, or synthesised proteins selected from the group comprising:'}optionally one or more plasticizers;optionally one or more co-initiators; andone or more crosslinkers.2. The biocompatible composition according to claim 1 , wherein said one or more proteins are crosslinkable to form a polymer.3. The biocompatible composition according to or claim 1 , wherein the biocompatible composition is an in vivo gelling composition formulated to at least in part polymerise and/or gel at a target site in or on a subject's body claim 1 , or wherein the biocompatible composition is an in vivo gelling composition formulated such that crosslinking of the in vivo gelling composition occurs or is initiated when present at a target site in or on a subject's body.4. A method for producing a crosslinked biopolymer composition claim 1 , the method comprising:{'claim-text': ['a. an α-crystallin;', 'b. a β- ...

Подробнее
Номер записи: 52
24-03-2022 дата публикации

Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof

Номер: US20220088266A1
Автор: Lei Fang, Shuai Yajun, Yang Mingying
Принадлежит:

The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen. 1. A blood coagulation-promoting silk fibroin-polypeptide electrospun membrane , wherein the polypeptide has a sequence of GPRPPSEHLQIT (SED ID NO: 1).2. The silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein the electrospun membrane is made of interwoven silk fibroin nanofibers claim 1 , and the polypeptide is evenly distributed in the nanofibers.3. A preparation method of the blood coagulation-promoting silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein specific preparation steps adopted are as follows:1) dissolving, filtering, dialyzing, concentrating, freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder;2) evenly mixing the silk fibroin freeze-dried powder and the polypeptide GPRPPSEHLQIT (SED ID NO: 1) with a hexafluoroisopropanol solvent;3) electrospinning a mixed solution obtained in step 2) to obtain a silk fibroin-polypeptide electrospun membrane.4. The preparation method of the silk fibroin-polypeptide electrospun membrane according to claim 3 , wherein the mass ratio of the silk fibroin freeze-dried powder:the hexafluoroisopropanol solvent used in the step 2) is 2: 98-20:80.5. The preparation method of the silk fibroin- ...

Подробнее
Номер записи: 53
19-03-2015 дата публикации

Device having osteoinductive and osteoconductive properties

Номер: US20150080303A1
Автор: Klaus Hellerbrand, Peter Happersberger, Sylke Pohling, Ulrich Kohnert
Принадлежит: SCIL TECHNOLOGY GMBH

The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.

Подробнее
Номер записи: 54
14-03-2019 дата публикации

CATIONIC STEROIDAL ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF DERMAL TISSUE

Номер: US20190076581A1
Автор: Bracken Ronald, Genberg Carl, Savage Paul B.
Принадлежит:

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application. 1. A dermal filler composition for injection into dermal tissue , comprising:a biologically compatible dermal filler material in the form of a liquid, gel, paste, or viscous material so as to be syringe-injectable into dermal tissue; andone or more cationic steroidal antimicrobial (CSA) compounds incorporated into the biologically compatible dermal filler material so that, when injected into soft tissue, the dermal filler composition can form a bolus having a reservoir of CSA compounds incorporated into and distributed within a matrix of the dermal filler composition and provide effective time release of the one or more CSA compounds from the dermal filler material.2. The dermal filler composition of claim 1 , wherein the dermal filler comprises one or more syringe-injectable bioabsorbable materials.3. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable hyaluronic acid.4. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable collagen.5. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable hydroxyapatite mineral.6. ...

Подробнее
Номер записи: 55
22-03-2018 дата публикации

ANTI-ADHESION MATERIAL AND SUBSTITUTE BIOMEMBRANE USING DECELLULARIZED TISSUE

Номер: US20180078679A1
Автор: FUNAMOTO Seiichi, HIGAMI Tetsuya, Hiwatari Ken-ichiro, Kimura Tsuyoshi, KISHIDA Akio, NEGISHI Jun, OBARA Haruki, Saga Hideki, TOKOROZAKI Shoko, UCHIDA Takanori
Принадлежит:

An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue. 1. An anti-adhesion material comprising decellularized tissues and a biocompatible polymer.2. The anti-adhesion material of wherein the decellularized tissues are the ones prepared by decellularizing biological tissues selected from the group consisting of pericardium claim 1 , bladder claim 1 , amnion claim 1 , dura mater claim 1 , peritoneum claim 1 , diaphragm claim 1 , fascia claim 1 , small intestine submucosa and skin.3. The anti-adhesion material of or wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.4. The anti-adhesion material of wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1 claim 3 ,500 MPa to biological tissues in a medium.5. The anti-adhesion material of any one of to wherein the biocompatible polymer is a biocompatible polymer which naturally occurs.6. The anti-adhesion material of any one of to wherein the biocompatible polymer is fibrin glue.7. The anti-adhesion material of any one of to wherein the biocompatible polymer is complexed to the decellularized tissues.8. The anti-adhesion material of wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the ...

Подробнее
Номер записи: 56
31-03-2022 дата публикации

HEMOSTATIC MATERIAL

Номер: US20220096707A1
Автор: Arakane Toru, Kurumatani Hajimu, Nakahara Keiko, Nakahara Makoto, Nishiura Mamoru, Otsubo Shinya, Oyama Kumi, Takeda Masanobu, Takeoka Shinji
Принадлежит: Toray Industries, Inc.

A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids. 115-. (canceled)16. A hemostatic material comprising a water-insoluble base and a lipid supported on a surface of the base , wherein the lipid comprises one or two or more anionic lipids.17. The hemostatic material according to claim 16 , wherein the base is a porous base claim 16 , and the lipid is supported on a surface of a pore of the porous base.18. The hemostatic material according to claim 17 , wherein the lipid accounts for at least a part of the pore of the porous base.19. The hemostatic material according to claim 17 , wherein the porous base is a fiber base.21. The hemostatic material according to claim 20 , wherein the amino acid residue represented by Mis an acidic amino acid residue or a neutral amino acid residue.22. The hemostatic material according to claim 21 , wherein the acidic amino acid residue is an aspartic acid residue or a glutamic acid residue.23. The hemostatic material according to claim 20 , wherein the residue of the amino acid derivative represented by Mis a residue of a basic amino acid derivative claim 20 , and an introduced derivatization that the basic amino acid derivative comprises is amidation of an amino group of a side chain of a basic amino acid to a group represented by a: —NH—CO—Rwherein —NH— is derived from the amino group of the side chain of the basic amino acid claim 20 , and Rrepresents a hydrocarbon group.24. The hemostatic material according to claim 20 , wherein the peptide residue represented by Mis a peptide residue comprising one or two or more acidic amino acid residues.25. The hemostatic ...

Подробнее
Номер записи: 57
31-03-2022 дата публикации

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

Номер: US20220096708A1
Автор: Chen Shuang, Feng Dengmin, Li Yufu, Wan Xiang
Принадлежит:

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; and thus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether C4F9OCH3.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size ...

Подробнее
Номер записи: 58
12-03-2020 дата публикации

PANCREATIC FISTULA OCCLUSION

Номер: US20200078489A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for occluding a pancreatic fistula are described herein. One method for occluding a pancreatic fistula includes administering an effective amount of a self-assembling peptide solution to a pancreatic fistula, where the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions, thereby occluding the pancreatic fistula. 1. A method for occluding a pancreatic fistula , the method comprising administering an effective amount of a self-assembling peptide solution to a pancreatic fistula , wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions , thereby occluding pancreatic fistula.2. The method of claim 1 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and a hydrophilic amino acids.3. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from RADA claim 1 , IEIK claim 1 , TTTT claim 1 , ATAT claim 1 , TVTV claim 1 , ASAS claim 1 , SSSS claim 1 , VVVTTTT claim 1 , and a combination thereof.4. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from (RADA) claim 1 , (IEIK)I claim 1 , and (KLDL).5. The method of claim 1 , wherein the self-assembling peptide is about 0.1 to about 10 w/v % of the solution or about 0.1 to about 3.5 w/v % of the solution.6. The method of claim 1 , wherein the self-assembling peptide is about 1 claim 1 , about 2.5 claim 1 , or about 3 w/v % of the solution.7. The method of claim 1 , wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof target area.8. The method of claim 1 , wherein the effective amount is approximately 1 mL per 1 cmof target area.9. The method of claim 1 , wherein the hydrogel is formed ...

Подробнее
Номер записи: 59
12-03-2020 дата публикации

USE OF SELF-ASSEMBLING POLYPEPTIDES AS TISSUE ADHESIVES

Номер: US20200078490A1
Автор: Leimer Axel, Maksimovikj Nathalie, Römer Lin, Schmidt Martin
Принадлежит:

The present invention relates to a self-assembling polypeptide for use as tissue adhesive. The present invention also relates to the use of a self-assembling polypeptide as tissue adhesive. Further, the invention is directed to the use of a self-assembling polypeptide to glue one or more cosmetic compounds on skin, mucosa, and/or hair. Furthermore, the invention is directed to a self-assembling polypeptide for use in gluing one or more pharmaceutical compounds on tissue, skin, mucosa, and/or hair. 155.-. (canceled)56. A method for adhering tissue comprising the steps of:(i) providing a self-assembling polypeptide,(ii) applying the self-assembling polypeptide to at least one of at least two tissue layers, thereby coating the at least one of the at least two tissue layers with the self-assembling polypeptide, and(iii) contacting the at least two tissue layers, thereby adhering the at least two tissue layers together.57. The method of claim 56 , wherein said polypeptide further comprises at least one peptide which is capable of enhancing the adhesive effect.58. The method of claim 57 , wherein the adhesive effect is mediated via binding of the peptide to a cell adhesion mediating protein (CAMP).59. The method of claim 58 , wherein the peptide comprises at least one CAMP recognition sequence.60. The method of claim 59 , wherein the CAMP recognition sequence comprises a module containing RGD claim 59 , GER claim 59 , GEK claim 59 , GEN claim 59 , IDAPS (SEQ ID NO: 45) or variants thereof claim 59 , GPR claim 59 , HHLGGAKQAGDV (SEQ ID NO: 46) or variants thereof claim 59 , CDPGYIGSR (SEQ ID NO: 47) or variants thereof claim 59 , AEIDGIEL (SEQ ID NO: 48) or variants thereof claim 59 , QIDS (SEQ ID NO: 49) claim 59 , or LTD.61. The method of claim 56 , wherein the self-assembling polypeptide is a silk polypeptide.62. The method of claim 61 , wherein the silk polypeptide is selected from the group consisting of ADF-3 (SEQ ID NO: 1) or variants thereof claim 61 , ADF-4 (SEQ ...

Подробнее
Номер записи: 60
29-03-2018 дата публикации

ADHESIVE PEPTIDE AND USE THEREFOR

Номер: US20180085488A1
Автор: YOON Won-Joon
Принадлежит:

Disclosed are novel peptides with adhesive properties to various materials of biological or non-biological origins. 1. An isolated polypeptide having an amino acid sequence consisting of the amino acid sequence as set forth in SEQ ID NO: 1 , 6 , 15-22 , 24-27 , 29-37 , 42-64 , 67 or 68.2. The polypeptide of claim 1 , wherein the first amino acid of SEQ ID NO: 15-20 claim 1 , 22 claim 1 , 24-27 claim 1 , 30-37 claim 1 , 42-64 claim 1 , 67 and 68 is substituted with a lysine residue claim 1 , the first amino acid of SEQ ID NO: 21 is substituted with an arginine claim 1 , and the first amino acid of SEQ ID NO: 29 is substituted with an aspartic acid.3. The polypeptide of claim 1 , wherein the first amino acid of SEQ ID NO: 15- 22 claim 1 , 24-27 claim 1 , 30-37 claim 1 , 42-64 claim 1 , 67 and 68 is substituted with an aspartic acid or a glutamic acid residue claim 1 , and the first amino acid of SEQ ID NO: 29 is substituted with a lysine or arginine residue.4. The polypeptide of claim 1 , wherein the amino acid sequence of SEQ ID NO: 15-20 claim 1 , 22 claim 1 , 24-27 claim 1 , 30-37 claim 1 , 42-64 claim 1 , 67 or 68 further comprise up to 14 arginine residues at the N-terminus claim 1 , the amino acid sequence of SEQ ID NO: 21 further comprises up to 14 lysine residues at the N-terminus claim 1 , and the amino acid sequence of SEQ ID NO:29 further comprises up to 14 glutamic acid residues.5. The polypeptide of claim 1 , wherein the N or C-terminal of the polypeptide is substituted with an inert group.6. A composition comprising the polypeptide of .7. A nucleic acid molecule encoding the polypeptide of .8. A vector comprising the nucleic acid molecule of .9. A cell comprising the vector of .10. A method of attaching a first biological or non-biological material to a second biological material or non-biological material by treating the first and/or the second material with the peptide of . The present application is a continuation in part application of International ...

Подробнее
Номер записи: 61
30-03-2017 дата публикации

COLLAGEN BASED MATERIALS AND METHODS OF USING THEM

Номер: US20170087272A1
Автор: Berlowitz Laurence J, Claesson Hans P.I., Fullana Matthew, Wnek Gary E
Принадлежит:

Certain configurations of adhesive materials are described which comprise a crosslinked derivatized atelocollagen. In some configurations, the crosslinked, derivatized atelocollagen is cured to provide a burst strength of at least 55 kPa or 60 kPa (or more) as tested by ASTM F2392-04. In some instances, the crosslinked derivatized atelocollagen comprises a methylated atelocollagen that is crosslinked using one or more functionalized crosslinking agents. 1. An adhesive/sealant material comprising a crosslinked , derivatized atelocollagen that provides a burst strength of about 60 kPa or more after curing as tested by ASTM F2392-04.2. The adhesive/sealant material of claim 1 , in which the derivatized atelocollagen is an alkylated mammalian atelocollagen or a methylated atelocollagen claim 1 , in which the alkylated or methylated derivatized atelocollagen comprises:a number average molecular weight of about 300 kDa; ora number average molecular weight of about 300 kDa to about 600 kDa; ora number average molecular weight of less than 300 kDa.3. The adhesive/sealant material of claim 1 , in which the crosslinked claim 1 , derivatized atelocollagen is cured with a solid curing agent to provide the burst strength of about 60 kPa or more after curing as tested by ASTM F2392-04.4. The adhesive/sealant material of claim 1 , in which the crosslinked claim 1 , derivatized atelocollagen is crosslinked with a polyethylene glycol crosslinking agent.5. The adhesive/sealant material of claim 4 , in which the polyethylene crosslinking agent comprises at least one of a succinimidyl group claim 4 , a sulfhydryl group or an amino group.6. The adhesive/sealant material of claim 4 , in which the polyethylene glycol crosslinking agent comprises a first crosslinking agent comprising at least one electrophilic group and a second crosslinking agent comprising at least one nucleophilic group.7. The adhesive/sealant material of claim 1 , in which the crosslinked claim 1 , derivatized ...

Подробнее
Номер записи: 62
19-06-2014 дата публикации

METHODS AND COMPOSITIONS SUITABLE FOR IMPROVED REATTACHMENT OF DETACHED CARTILAGE TO SUBCHONDRAL BONE

Номер: US20140170106A1
Автор: Burdon Drew, Carvell Kelsey Jean, Cheng Ruth, Smith Graham
Принадлежит:

The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage. 1. A method for promoting the reattachment of cartilage to bone at a cartilage-bone interface where the delaminated cartilage includes an acellular surface , said method comprising:administering one or more agents to the delaminated cartilage-bone interface, where the agent(s) are suitable for promoting the controlled degradation of the acellular cartilage layer, thereby promoting conditions for the reattachment of said delaminated cartilage to said bone.2. The method of claim 1 , wherein said agent for promoting the controlled degradation of the acellular cartilage layer comprises one or more compositions selected from the group consisting of a poly glycolic acid (PGA) lattice claim 1 , cytokines claim 1 , collagenase claim 1 , hyaluronidase and a material comprising a crystalline compound.3. The method of claim 2 , wherein the material comprising a crystalline compound comprises a depo-corticosteroid.4. The method of claim 1 , wherein said method additionally comprises subchondral disruption of the bone surface.5. The method of claim 1 , wherein said method additionally comprises at least partial removal of calcified cartilage from the bone surface.6. The method of claim 5 , wherein said subchondral disruption of the bone surface removes from approximately 0.02 mm to approximately 3.0 mm of tissue from the surface.7. The method of claim 1 , wherein said controlled degradation of said acellular layer comprises promoting an inflammatory reaction.8. The method of claim 1 , wherein said method additionally comprises administering a biophysically compatible glue or adhesive agent to the cartilage-bone ...

Подробнее
Номер записи: 63
05-04-2018 дата публикации

Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof

Номер: US20180093010A1
Автор: Bar Liliana, Meidler Roberto, Nur Israel
Принадлежит:

The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or methods for promotion of blood coagulation sealing or filling body surfaces. 127-. (canceled)28. A method of preparing a fibrin glue at a surface comprising: providing a solution A—comprising fibrinogen; providing a solution B—comprising a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen and an enzymatically-permissive concentration of a visualization agent; applying a defined volume of the solutions to said surface so as to cause clotting of the fibrin.29. The method according to claim 28 , wherein the concentration of the visualization agent in the generated glue is in the range of from about 0.0025 to about 0.1% claim 28 , or from about 0.0025 to about 0.01%.30. The method according to or claim 28 , wherein solutions A and B are applied to said surface simultaneously.31. The method according to any one of to claim 28 , wherein the proteolytic enzyme is thrombin.32. The method according any one of to claim 28 , wherein solution A further comprises a catalyst capable of inducing cross-linking of fibrin.33. The method according to claim 32 , wherein the catalyst is a transglutaminase.34. The method according to claim 33 , wherein the transglutaminase is Factor XIII.35. The method according to any one of to claim 33 , wherein the visualization agent is selected from the group consisting of methylene blue claim 33 , indigo carmine and combinations thereof.36. The method according to claim 35 , wherein the visualization agent is methylene blue.37. The method according to any one of to claim 35 , wherein solution B is protected from light.38. The method according to claim 35 , wherein the visualization agent is indigo ...

Подробнее
Номер записи: 64
12-04-2018 дата публикации

REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF

Номер: US20180099070A1
Автор: Stewart Russell J.
Принадлежит: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Described herein is the synthesis of reinforced adhesive complex coacervates and their use thereof. The reinforced adhesive complex coacervates are composed of (a) at least one polycation, (b) at least one polyanion, and (c) a reinforcing component. The adhesive complex coacervates described herein can be subsequently cured to produce strong, cohesive adhesives. The reinforced adhesive complex coacervates have several desirable features when compared to conventional adhesives. The reinforced adhesive complex coacervates are effective in wet or underwater applications. The reinforced adhesive complex coacervates described herein, being phase separated from water, can be applied underwater without dissolving or dispersing into the water. The reinforced adhesive complex coacervates have numerous biological applications as bioadhesives and bioactive delivery devices. In particular, the reinforced adhesive complex coacervates described herein are particularly useful in underwater applications and situations where water is present such as, for example, wet tissues in physiological conditions. 1. An associative liquid adhesive complex coacervate , wherein the liquid adhesive complex coacervate comprises (a) at least one polycation , (b) at least one polyanion , and (c) a reinforcing component comprising a water-insoluble solid.2. The associative liquid adhesive complex coacervate of claim 1 , wherein the polycation comprises a polyamino compound.3. The associative liquid adhesive complex coacervate of claim 1 , wherein the polycation comprises a polysaccharide claim 1 , a natural protein claim 1 , a recombinant protein claim 1 , or a synthetic polyamine.4. The associative liquid adhesive complex coacervate of claim 1 , wherein the polycation comprises an alkylamino group claim 1 , a heteroaryl group claim 1 , a guanidinyl group claim 1 , or an aromatic group substituted with one or more amino groups.5. The associative liquid adhesive complex coacervate of claim 1 , wherein ...

Подробнее
Номер записи: 65
08-04-2021 дата публикации

Elastic Biopolymer and Use as a Tissue Adhesive

Номер: US20210100928A1
Автор: Annabi Nasim, ASSMANN Alexander, Khademhosseini Ali
Принадлежит:

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics. 175.-. (canceled)76. A tissue adhesive comprising a light activated methacryloyl-substituted gelatin , a photoinitiator and a pharmaceutically acceptable carrier.77. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin has a degree of methacryloyl substitution between 50% and 90%.78. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin is present at a concentration between 10% and 40% (w/v).79. The tissue adhesive of claim 76 , wherein the photoinitiator is selected from the group consisting of: 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one claim 76 , azobisisobutyronitrile claim 76 , benzoyl peroxide claim 76 , di-tert-butyl peroxide claim 76 , 2 claim 76 ,2-dimethoxy-2-phenylacetophenone claim 76 , Eosin Y claim 76 , and any combination thereof.80. The tissue adhesive of claim 76 , further comprising:(i) a hemostatic agent selected from the group consisting of blood ...

Подробнее
Номер записи: 66
02-06-2022 дата публикации

VASCULAR EMBOLIC SYSTEM

Номер: US20220168462A1
Автор: Kobayashi Satoru, Takamura Kentaro
Принадлежит: 3-D Matrix, Ltd.

Systems and methods of blocking a biological vessel are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation. 1. A method of blocking one or more targeted biological vessels in a subject comprising:introducing a catheter into a target biological vessel;positioning an end of the catheter in, near, upstream or downstream from a target area of a biological vessel in which at least a partial obstruction of the vessel is desired;administering through the catheter a solution comprising an amphiphilic peptide comprising at least 12 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid in an effective amount and in an effective concentration to form a hydrogel at the target site the hydrogel thereby forming at least a partial blockage of the target biological vessel;removing the catheter from the biological vessel with the at least partial obstruction in place.2. The method of claim 1 , wherein the peptide solution comprises a contrast agent.3. The method of claim 2 , further comprising visualizing a region comprising at least a portion of the targeted biological vessel or vessels.4. The method of claim 3 , wherein visualizing the region comprising at least a portion of the biological vessel comprises visualizing the region during at least one of:identifying the target area of the biological vessel;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andvisualizing the biological vessel after removing the catheter.5. The method of claim 4 , wherein visualizing the region comprises imaging using X-ray radiography.6. The method of claim 3 , wherein visualizing the region provides for ...

Подробнее
Номер записи: 67
03-07-2014 дата публикации

Single Component Fibrin Hemostat

Номер: US20140187492A1
Автор: Falus George David, Medved Leonid
Принадлежит:

ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application. 1. A composition for the control of bleeding with or without compression comprising the following two components homogenized into a single colloidal solution at the time of use:a) a crosslinked lyophilized/homogenized desAB fibrin (fibrin II) polymer suspended in acetic acid solution at a concentration ranging from 6 mg/mL to 24 mg/mL,b) a desAB fibrin (fibrin II) monomer in acetic acid solution or sodium acetate at a concentration ranging from 6 mg/mL to 24 mg/mL.2. The composition as claimed in wherein the acetic acid solution or sodium acetate buffer has a pH of 3.4-4.0.3. The composition as claimed in wherein the lyophilized fibrin polymer is washed with acetic acid solution in order to adjust final pH value to 3.4-3.5.4. The composition as claimed in wherein prior to lyophilization claim 1 , the fibrin polymer is crosslinked in the presence-of calcium-independent transglutaminase enzyme.5. The composition as claimed in wherein both the fibrin monomer and the fibrin polymer are depleted of thrombin by a dialysis process.6. The composition as claimed in wherein the components can be rendered sterile claim 1 , are non-toxic claim 1 , do not affect growth of human fibroblasts (HF) or human epithelial cells and therefore is characterized as being ...

Подробнее
Номер записи: 68
20-04-2017 дата публикации

COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING

Номер: US20170106116A1
Автор: FALANGA Vincent
Принадлежит:

Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds. 1. A fibrin sealant comprising a fibrinogen complex (FC) component , a thrombin component , and a cellular component , wherein concentration of fibrinogen used to form the gel is between from about 2 to about 5 mg/ml , wherein the cellular component comprises one or more of stem/progenitor cells , and wherein the fibrin sealant comprises at least 1.5-2.0×10stem/progenitor cells/cm.2. The composition of claim 1 , stem/progenitor cells are selected from the group consisting of bone marrow derived cells claim 1 , hematopoietic stem cells claim 1 , mesenchymal stem cells claim 1 , peripheral blood stem cells claim 1 , and mixtures and combinations thereof.3. The composition of claim 1 , wherein the stem/progenitor cells are bone marrow derived cells.4. The composition of claim 1 , wherein the stem/progenitor cells are mesenchymal stem cells.5. The composition of claim 1 , wherein the stem/progenitor cells are peripheral blood stem cells.6. A method of using a fibrin sealant claim 1 , comprising: a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant claim 1 , said fibrin sealant comprising calcic thrombin and fibrinogen claim 1 , wherein the concentration of calcic thrombin is about 25 U/ml claim 1 , wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml claim 1 , and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×10stem/progenitor cells/cm; b) administering the fibrin sealant to a cutaneous wound claim 1 , wherein the fibrin sealant is administered in the form of a polymerized gel or spray.7. The method of claim 6 , wherein the fibrin sealant is administered to the site of the wound at least two times over the span of three weeks.8. The method of claim 6 , stem/progenitor cells are bone marrow derived cells ...

Подробнее
Номер записи: 69
28-04-2016 дата публикации

PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE

Номер: US20160114075A1
Автор: Brownlee Alan George, Elvin Christopher Malcolm, Lindall Charles Mark, Ramshaw John Alan Maurice, Werkmeister Jerome Anthony
Принадлежит:

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial. 152-. (canceled)53. A method of crosslinking a protein or peptide for use as a tissue sealant , the method comprising:irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a three-dimensional matrix of the tissue sealant.54. The method of claim 53 , wherein the protein or peptide comprises fibrinogen claim 53 , fibrin claim 53 , collagen claim 53 , fibronectin claim 53 , keratin claim 53 , laminin claim 53 , and/or elastin.55. The method of claim 53 , wherein the protein or peptide is isolated from native tissues.56. The method of claim 53 , wherein the protein or peptide is a recombinant protein or peptide.57. The method of claim 53 , wherein the electron acceptor is a persulfate.58. The method of claim 57 , wherein the persulfate is ammonium persulfate or sodium persulfate.59. The method of claim 53 , wherein the photoactivatable metal-ligand complex is an Ru(II) complex.60. The method of claim 59 , wherein the photoactivatable metal-ligand complex is a Ru(II)bipyridyl complex.61. The method of claim 60 , wherein the photoactivatable metal-ligand complex is a tris(bipyridyl)Ru(II) complex62. A method of joining and/or sealing at least one substrate claim 60 , comprising the steps of:applying a tissue sealant comprising: a matrix protein or peptide, a photoactivatable metal-ligand complex, and an electron acceptor to at least one substrate; andirradiating the material to photoactivate the photoactivatable metal-ligand complex, thereby initiating a cross-linking reaction to adhere or join the substrate to an adjacent substrate.63. The ...

Подробнее
Номер записи: 70
26-04-2018 дата публикации

USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING

Номер: US20180110814A1
Автор: Egana-Erazo Jose-Tomas, Hopfner Ursula, Machens Hans-Gunther, Nickelsen Joerg
Принадлежит:

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia. 1. A composition comprising photosynthetic cells.2. The composition of claim 1 , wherein the photosynthetic cells are algae cells.3. The composition of claim 2 , wherein the algae cells are unicellular algae cells.4Chlamydomonas.. The composition of claim 3 , wherein the unicellular algae cells are from the genus5ChlamydomonasChlamydomonas reinhardtii.. The composition of claim 4 , wherein the is6. The composition of claim 1 , wherein the photosynthetic cells are encapsulated with a permeable immunologically inert material.7. The composition of claim 6 , wherein the permeable immunologically inert material is a natural or synthetic polymer.8. The composition of claim 7 , wherein the natural or synthetic polymer is a hydrogel or alginate.9. The composition of claim 1 , wherein at least some of the photosynthetic cells are genetically engineered cells.10. The composition of claim 5 , wherein at least some of the photosynthetic cells have been genetically engineered to contain nucleic acids encoding for at least one bioactive molecule.11. The composition of claim 1 , for use ex vivo.12. The composition of claim 1 , for use in vivo.13. A composition comprising photosynthetic cells configured for use claim 1 , in a subject claim 1 , in a method selected from the group consisting of: treatment of hypoxia; treatment of ischemia claim 1 , in vivo implantation claim 1 , treatment or prevention of inflammation claim 1 , treatment of damage of tissue selected from skin claim 1 , nerve claim 1 , bone claim 1 , cartilage or blood tissue.14. The composition of claim 13 , for use ex vivo.15. The composition of claim 11 , for use in vivo. This application is a divisional of U.S. patent application Ser. No. 14/869,930, filed on Sep. 29, 2015, which is a continuation of U.S. patent application Ser. No. 13/636,402, filed on Dec. 20, ...

Подробнее
Номер записи: 71
05-05-2016 дата публикации

EXTEMPORANEOUS PREPARATION OF AUTOLOGOUS FIBRIN

Номер: US20160121036A1
Автор: EVERTS Peter, JOOS Michael
Принадлежит:

An Autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically. 1. A device for enriching the fibrinogen content of a plasma fraction comprising three interconnected chambers each of them fitted with an inlet and/or an outlet , connecting means for transferring fluid flows from one chamber to another one provided with either means for controlling said fluid flows and/or means for moving said fluid flows from one chamber to another one or to the outside , which comprises:a treatment chamber provided with internal filtering means,a first expandable storing chamber connected to chamber, anda second expandable chamber connected to chamber in such a way to establish a closed circuit between said chambers and.2. The device according to wherein treatment chamber is connected to storing chamber either directly or via a one-way valve.3. The device according to wherein the transfer means connecting the treatment chamber and the second expandable chamber to form the closed circuit comprise multidirectional valves.4. The device according to wherein the means for moving fluid flows comprise a peristaltic pump.5. The device of which further comprises means for electromagnetic or visual contact and means for control and command and which is suited for encasing in a dedicated container.6. A method for enriching the fibrinogen content of a poor platelet plasma PPP fraction by means of the device of which comprises:introducing progressively a poor platelet plasma (PPP) fraction from chamber into treatment chamber while moving ...

Подробнее
Номер записи: 72
07-05-2015 дата публикации

METHOD FOR IMPROVED FIBRIN SEALING

Номер: US20150125440A1
Автор: ILAN Erez, Nur Israel, REGEV KFIR
Принадлежит:

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue. 122-. (canceled)23. A method for treating or preventing a defect in a moist tissue of a subject in need comprising the steps of:a) providing a component comprising solid fibrinogen, providing a component comprising a solid proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen; and providing a liquid fibrin sealant formulation;b) applying an effective amount of the solid components of a) onto at least a part of the moist tissue; andc) applying over at least a portion of the applied solid components an effective amount of the liquid fibrin sealant formulation of a).24. The method according to claim 23 , wherein the moist tissue is not enriched claim 23 , has small amount claim 23 , is deprived or lacks blood vessels and/or is an oozing or non-bleeding tissue.25. The method according to claim 23 , wherein the defect is a leak in the tissue.26. The method according to claim 25 , wherein the leaking substance is not enriched claim 25 , has small amount claim 25 , is deprived or lacks plasma or blood components.27. The method according to claim 23 , wherein the liquid fibrin sealant formulation is provided in solid form and reconstituted prior to its application.28. The method according to claim 23 , wherein the liquid fibrin sealant formulation is provided in frozen form and thawed prior to its application.29. The method according to claim 23 , wherein the solid component is provided in liquid form and dried prior to its application.30. The method according to claim 23 , wherein the solid component is provided in frozen form and dried prior to its application.31. The method according to claim 23 , wherein the solid components are applied simultaneously or one after the other.32. The method according to claim 23 , wherein the liquid components are applied simultaneously or one after the other.33. The ...

Подробнее
Номер записи: 73
25-08-2022 дата публикации

COLLAGEN MATRIX AND N-HYDROXYLSUCCINIMIDE FUNCTIONALIZED POLYETHYLENE GLYCOL STAPLE LINE REINFORCEMENT

Номер: US20220265273A1
Автор: Daller Justin Robert, Foley John, Fulghum Tim, Lewis Kevin Michael
Принадлежит:

Disclosed herein are surgical staple line reinforcement materials and methods of production and use thereof. 1. A method for treating a surgical staple line comprising applying to the line a biocompatible substrate coated with a self-expanding polymer.2. The method of claim 1 , wherein said biocompatible substrate comprises collagen.3. The method of claim 2 , wherein said self-expanding polymer comprises PEG.4. The method of claim 3 , wherein said PEG comprises NHS-PEG.5. The method of claim 1 , wherein said surgical line is associated with a bariatric procedure.6. The method of claim 1 , wherein said surgical line is associated with a gastric procedure.7. The method of claim 1 , wherein said surgical line is associated with a lung procedure.8. The method of claim 1 , wherein said surgical line is associated with a bowel procedure.9. The method of claim 8 , wherein said bowel procedure comprises a small bowel procedure.10. A device for treating a surgical staple line claim 8 , said device comprising a biocompatible matrix and a self-expanding polymer.11. The device of claim 10 , wherein said biocompatible matrix comprises collagen.12. The device of claim 10 , wherein said self-expanding polymer comprises PEG.13. The device of claim 12 , wherein said PEG comprises NHS-PEG.14. The device of claim 10 , further comprising a pressure-sensitive adhesive.15. A kit for use in treatment of surgical staple lines claim 10 , comprising;a biocompatible substrate coated with a self-expanding polymer; andat least one administration device, buffer solution, syringe, tube, catheter, forceps, scissors, sterilizing pad or lotion.16. The kit of claim 15 , wherein said biocompatible substrate comprises collagen.17. The kit of claim 15 , wherein said self-expanding polymer comprises PEG.18. The kit of claim 16 , wherein said self-expanding polymer comprises NHS-PEG.19. A method of manufacturing a device for treating a surgical staple line claim 16 , said device comprising a biocompatible ...

Подробнее
Номер записи: 74
25-04-2019 дата публикации

FIBRIN AND/OR DIALDEHYDE STARCH HYDROLYSATE MATERIALS, AND PREPARATION AND USE THEREOF

Номер: US20190117825A1
Автор: Davisson Brooke Lynn, Ramachandran Niraj
Принадлежит: Cook Biotech Incorporated

Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlled hydrolysis, desirably base-catalyzed, to prepare a fibrin hydrolysate material with increased water sorption capacity. Such fibrin hydrolysate materials, alone or combined with one or more additional substances, can be used in the preparation of hemostasis promoting foams, powders or gels. In some embodiments, a starting dialdehyde starch material is subjected to controlled hydrolysis to prepare a dialdehyde starch hydrolysate material. Such dialdehyde starch hydrolysate materials, alone or combined with one or more additional substances, in some cases combined with a fibrin hydrolysate material, can be used in the preparation of hemostasis promoting foams, powders or gels. 1. A method for making a hemostasis promoting material , comprising:subjecting a fibrin-containing starting material to hydrolysis conditions so as to form a fibrin hydrolysate material having an increased sorption capacity, relative to the fibrin starting material, for water at a pH of 7.2. The method according to claim 1 , wherein the hydrolysis conditions comprise contacting the fibrin starting material with a basic liquid medium and/or wherein the fibrin hydrolysate material exhibits a sorption capacity for water at a pH of 7 and a temperature of 20° C. of at least about 10 times its dry weight.3. The method according to claim 1 , wherein the basic liquid medium has a pH in the range of about 10 to 14 and/or wherein the basic liquid medium comprises sodium hydroxide or potassium hydroxide.4. (canceled)5. The method of claim 1 , also comprising lyophilizing the fibrin hydrolysate material.6. (canceled)7. The method of claim 1 , wherein the subjecting is for a period of time of at least about 10 minutes claim 1 , more preferably wherein the period of time is ...

Подробнее
Номер записи: 75
25-04-2019 дата публикации

PROTEIN BIOMATERIAL AND BIOCOACERVATE VESSEL GRAFT SYSTEMS AND METHODS OF MAKING AND USING THEREOF

Номер: US20190117855A1
Автор: Masters David B.
Принадлежит:

The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention. 1. A fastener comprising one or more components , at least one of the components including a biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervates , the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents.2. The fastener of wherein the one or more primary proteins are selected from the group consisting of collagen claim 1 , laminin claim 1 , bone morphogenic protein and its isoforms that contain glycosaminoglycan binding sites claim 1 , albumin claim 1 , interleukins claim 1 , epidermal growth factors claim 1 , fibronectin claim 1 , thrombin claim 1 , aprotinin and antithrombin III.3. The fastener of wherein the one or more glycosaminoglycans are selected from the group consisting of heparin claim 1 , heparin sulfate claim 1 , keratan sulfate claim 1 , dermatin claim 1 , dermatin sulfate claim 1 , heparin-hyaluronic acid claim 1 , chondroitin claim 1 , chondroitin sulfate claim 1 , chondroitin 6-sulfate claim 1 , chondroitin 4-sulfate claim 1 , chitin claim 1 , chitosan claim 1 , acetyl-glucosamine claim ...

Подробнее
Номер записи: 76
27-05-2021 дата публикации

DUAL SYRINGE CARTRIDGE AND HOUSING

Номер: US20210153856A1
Автор: Cohn Simon, Guo Jianxin, Kokinelis Christopher Anthony, Schneider Jared
Принадлежит:

A dispensing device and cartridge for simultaneous delivery and mixing of multiple co-reactive materials, the cartridge having proximal and distal ends, and having an elongated holder body with substantially parallel longitudinal voids. Multiple syringe bodies are disposed parallel within the voids and multiple co-reactive materials are separately disposed in the syringe bodies. The dispensing device also includes a longitudinal housing which is structured and arranged to receive the cartridge. 1. A cartridge for storage and delivery of multiple co-reactive materials comprising:an elongated holder body having substantially parallel longitudinal voids with windows into each of the substantially parallel longitudinal voids;multiple hollow cylindrical bodies disposed substantially parallel within said longitudinal voids, said co-reactive materials separately disposed in said multiple hollow cylindrical bodies,wherein the multiple hollow cylindrical bodies have open proximal ends, nozzles at distal ends thereof, and pistons positioned inside, said pistons sealing the open proximal end and slidably moveable within the hollow cylindrical bodies and having no plungers attached.2. The cartridge of claim 1 , further comprising removable closure caps sealing the nozzles.3. The cartridge of claim 1 , further comprising a removable rear closure cap having plugs fitting into the open proximal ends of said multiple claim 1 , substantially parallel hollow cylindrical bodies.4. The cartridge of claim 1 , wherein the open proximal ends have diameters substantially the same as inner diameters of the hollow cylindrical bodies claim 1 , and the nozzles have Luer tapers.5. The cartridge of claim 1 , wherein the hollow cylindrical bodies are glass syringe bodies.6. The cartridge of claim 1 , wherein said co-reactive materials are fibrinogen and thrombin.7. The cartridge of claim 1 , wherein the holder body comprises a longitudinal groove between the substantially parallel longitudinal ...

Подробнее
Номер записи: 77
14-05-2015 дата публикации

Apparatus and Process for Providing a Coiled Collagen Carrier

Номер: US20150130112A1
Автор: Bertelsen Poul, Larsen Henrik Neuschafer, Pedersen Pernille Dybendal
Принадлежит:

The present invention relates inter alia to an apparatus for providing a coiled collagen carrier. An apparatus according to the invention preferably comprises a device for applying moisture to a collagen carrier prior to coiling of the collagen carrier and a coiling device. The coiling device preferably comprises rotatable gripping means for gripping the collagen carrier along an edge and coiling the collagen carrier, and a support device supporting the collagen carrier while being coiled. In another aspect, the invention relates to a production facility wherein an apparatus according to invention is arranged. 1. An apparatus for providing a coiled collagen carrier , the apparatus comprisinga device for applying moisture to a collagen carrier prior to coiling of the collagen carrier, rotatable gripping means for gripping the collagen carrier along an edge and coiling the collagen carrier, and', 'a support device for supporting the collagen carrier while being coiled., 'a coiling device comprising'}2. The apparatus according to claim 1 , wherein the gripping device comprises a pair of elongated members.351.-. (canceled)52. The apparatus according to claim 2 , wherein the pair of elongated members is a pair of tweezers or pincers.53. The apparatus according to claim 1 , wherein the support device is a cavity comprising a bottom shaped as a segment of a cylinder and having at least one open end claim 1 , and wherein the curved part of the cylinder segment extends at least 180°.54. The apparatus according to claim 53 , wherein the cavity is channel-formed with two parallel side walls extending from the bottom.55. The apparatus according to claim 2 , wherein the apparatus is further configured to move the pair of elongated members in reciprocating movement claim 2 , so that the elongated members can be retracted after the collagen carrier has been coiled.56. The apparatus according to claim 1 , further comprising a compressing device arranged to compress the moisturised ...

Подробнее
Номер записи: 78
12-05-2016 дата публикации

PROTEIN BASED MATERIALS

Номер: US20160129151A1
Автор: Brannum Daniel J., Fullana Matthew J., Wnek Gary E.
Принадлежит:

Gels and films can be formed from protein dissolved into a benign solvent that comprises alcohol, water, and salt. In one example, the protein can be collagen. In one example, the benign solvent can include a water to alcohol ratio of between ninety-nine-to-one and one-to-ninety-nine by volume, a salt concentration between zero moles per liter and the maximum salt concentration soluble in water, and a protein amount of between near zero percent and about 25 percent by weight as compared to the mixture of water and alcohol. Once the protein is dissolved in the benign solvent, secondary processing steps can be conducted to form protein based bioadhesives, gels, and films with desirable physical properties. Additional process steps can include washings that improve the properties of the protein structures. 1. A method for forming a protein structure from a benign solvent comprising:forming a benign solvent from water, alcohol, and salt;dissolving a protein in the benign solvent to form a protein solution;adding alcohol to the protein solution; andprecipitate a protein structure from the protein solution.2. The method of claim 1 , wherein the ratio of alcohol and salt in the benign solvent is about one-to-one by volume.3. The method of claim 1 , wherein the protein is a collagen.4. The method of claim 3 , wherein the collagen is a semed S bovine dermis-derived collagen powder comprising about 95 percent type I collagen and about 5 percent type III collagen.5. The method of claim 3 , wherein the collagen is dissolved in the benign solvent at about 17.5 percent by weight.61. The method of claim 3 , wherein the alcohol is added to the protein solution by titrating a two-to-one ratio by volume of alcohol to benign solvent.7. The method of claim 1 , wherein the protein structure is a gel.8. The method of claim 7 , further comprising the steps of:place the gel in water;stir to form a solution of the gel and water; andlyophilize the gel and water mixture to form a foam.9. The ...

Подробнее
Номер записи: 79
11-05-2017 дата публикации

SEALANT FORMULATION AND USES THEREOF

Номер: US20170128617A1
Автор: DeAnglis Ashley, Gorman Anne J.
Принадлежит:

The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade. 1. A sealant formulation comprising a blend containing fibrinogen and an activator of a member of a mammalian blood clotting cascade , wherein said activator is exogenous to said mammalian cascade and said member is upstream to fibrinogen in the mammalian's blood clotting cascade.2. The sealant formulation of claim 1 , wherein said blend is in dry form or is in a form of a liquid blend.3. The sealant formulation of claim 1 , wherein said blend comprises fibrinogen and the activator at a molar ratio of between 70 claim 1 ,000:1 and 25:1.4. The sealant formulation of claim 1 , wherein said member of the blood clotting cascade is a zymogen.5. The sealant formulation of claim 1 , wherein said activator is of non-human source.6. The sealant formulation of claim 1 , wherein said activator comprises venom claim 1 , a venom component or an analog of a venom component.7. The sealant formulation of claim 6 , wherein the venom component is selected from the group consisting of Ecarin claim 6 , Russell's Viper venom X factor (RVV-X) claim 6 , Russell's Viper venom V factor (RVV-V) claim 6 , Noscarin claim 6 , Oscutarin claim 6 , Trocarin claim 6 , Convulxin claim 6 , Botrocetin and any combination of said venom component.8. The sealant formulation of claim 1 , wherein the activator is a proteolytic enzyme active upstream to said member of the clotting cascade or a recombinant form of said proteolytic enzyme.9. The sealant formulation of claim 1 , wherein the activator is active on prothrombin.10. The sealant formulation of claim 1 , wherein the activator is active on factor X.11. The sealant formulation of claim 1 , wherein the activator is active on factor V.12. The sealant formulation of claim 1 , being free of thrombin or a functional analog of thrombin.13. The sealant formulation of claim 1 , comprising ...

Подробнее
Номер записи: 80
03-06-2021 дата публикации

MULTI-DIMENSIONAL HEMOSTATIC PRODUCT AND METHOD FOR PRODUCING THE SAME

Номер: US20210162095A1
Автор: CENTIS Valérie, Monchaux Emmanuelle
Принадлежит: BIOM'UP FRANCE SAS

The invention relates to a printed hemostatic product having at least three-dimensions and being made of a stack of layers deposited on one another from a first external layer up to a second external layer, wherein adjacent layers of the stack of layers are joined together, and wherein at least one layer of the stack of layers has at least one portion made from an hemostatic flowable with a composition comprising: non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; and—at least one monosaccharide. The invention also relates to a method for forming such an hemostatic product with a three-dimensional additive printer, and the use of an hemostatic flowable as a printing ink in such a three-dimensional additive printer. 1. A printed hemostatic product having at least three-dimensions and being made of a stack of layers deposited on one another from a first external layer up to a second external layer , wherein adjacent layers of the stack of layers are joined together , and wherein at least one layer of the stack of layers has at least one portion made from an hemostatic flowable with a composition comprising:non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; andat least one monosaccharide.2. The printed hemostatic product of claim 1 , wherein the at least one layer of the stack of layers has several portions made from hemostatic flowables with different compositions.3. The printed hemostatic product of claim 1 , wherein the at least one layer of the stack of layers is fully made from the same hemostatic flowable.4. The printed hemostatic product of claim 3 , wherein all layers of the stack of layers have the same composition.5. The printed hemostatic product of claim 3 , comprising a plurality of ...

Подробнее
Номер записи: 81
19-05-2016 дата публикации

PROCESS FOR PRODUCING HIGH PURITY FIBRINOGEN AND THROMBIN FOR FIBRIN SEALANT

Номер: US20160137719A1
Автор: CHAKRABORTY ZINIA, DUGGINENI SWAPNA SAGAR, KOMATH UMA DEVI, NUVULA ASHOK KUMAR, SAMADDAR MITALI, VADDE NEELIMA
Принадлежит:

The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities. The absence of plasminogen facilitates the exclusion of a proteolytic inhibitor (aprotinin) from among the kit components. 1. An integrated method for the isolation and purification of plasma derived fibrinogen and thrombin , without the use of ethanol precipitation , comprising subjecting plasma to gel filtration chromatography to obtain three fractions (Fraction I , Fraction II and Fraction III) which are subjected to further all-chromatographic steps followed by viral inactivation.2. A method according to comprises isolation followed by purification of fibrinogen claim 1 , involving:a) collection of a fraction from gel chromatography of human plasma;b) addition of ammonium sulphate to a concentration of 0.05M to 0.5M;c) loading on a hydrophobic column (HIC);d) conducting S/D virus inactivation for elute obtained from step c;e) subjecting the treated solution from step d to anion chromatography for further purification;f) conducting virus inactivation for achieving high levels of fibrinogen purity;g) filtration of the solution obtained from step f; andh) formulation and lyophilisation of the solution obtained from step g.3. A method according to comprises isolation followed by purification of thrombin claim 1 , involvinga) collection of a fraction through gel chromatography of human plasma;b) loading the fraction onto an anion exchange column equilibrated with a buffer comprising an acetate, citrate or similar salt with a molarity of 0.01 M to 0.1 M in the pH range of 6.5 to 8.5, eluting a partially purified prothrombin with the same buffer containing sodium chloride;c) conducting S/D virus inactivation for enveloped virus;d) collecting purified prothrombin by elution with a ...

Подробнее
Номер записи: 82
03-06-2021 дата публикации

FIBROUS PROTEINACEOUS NETWORKS AND METHODS OF USE THEREOF

Номер: US20210163558A1
Автор: Basavanna Avinash Manjula, Duraj-Thatte Anna, Joshi Neel Satish, Sourlis Arjirios
Принадлежит:

Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks. 1. An amyloid fusion protein comprising an amyloid protein fused to a fibrous protein.2. The amyloid fusion protein of claim 1 , wherein the amyloid protein is selected from the group consisting of CsgA and fragments thereof claim 1 , A-beta claim 1 , alpha-synuclein claim 1 , TasA claim 1 , and Sup35.3. The amyloid fusion protein of claim 1 , wherein the amyloid protein is CsgA claim 1 , or a fragment thereof.4. The amyloid fusion protein of claim 1 , wherein the fibrous protein is selected from the group consisting of keratin claim 1 , elastin claim 1 , fibrin claim 1 , and collagen claim 1 , or a fragment thereof.5. The amyloid fusion protein of claim 4 , wherein the fibrous protein is fibrin claim 4 , or a fragment thereof.6. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises an α chain of a fibrinogen.7. (canceled)8. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises a γ chain of a fibrinogen.9. (canceled)10. The amyloid fusion protein of claim 1 , wherein the fibrous protein is a keratin.11. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K5 keratin.12. (canceled)13. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K14 keratin.14. (canceled)15. A plurality of amyloid fusion proteins comprising a first amyloid fusion protein and a second amyloid fusion protein claim 10 ,wherein the first amyloid fusion protein comprises a first amyloid protein fused to a first fibrous protein; andwherein the second amyloid fusion protein comprises a second amyloid protein fused to a second fibrous protein,wherein the first fibrous protein is aggregated with the second fibrous protein.16. The plurality of amyloid fusion proteins of ...

Подробнее
Номер записи: 83
17-05-2018 дата публикации

FORMULATIONS AND KITS FOR FORMING BIOADHESIVE MATRICES

Номер: US20180133164A1
Автор: Cohen Binyamin, Foox Maytal, Shefy-Peleg Adaya, ZILBERMAN Meital
Принадлежит: Technology Innovation Momentum Fund (Israel) Limited Partnership

A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed. 1. A kit for preparing a bioadhesive formulation , comprising sub-formulation A and sub-formulation B , said sub-formulation A comprises gelatin and alginate dissolved in water and said sub-formulation B comprises a carbodiimide , whereas combining said sub-formulation A with said sub-formulation B affords the bioadhesive formulation , the bioadhesive formulation being for forming a bioadhesive matrix upon allowing a curing time to elapse , and wherein upon said combining:a concentration of said gelatin in the bioadhesive formulation ranges from 50 mg/ml to 400 mg/ml,a concentration of said alginate in the bioadhesive formulation ranges from 10 mg/ml to 60 mg/ml, anda concentration of said carbodiimide in the bioadhesive formulation ranges from 5 mg/ml to 50 mg/ml,such that prior to curing, the bioadhesive formulation is characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec, and such that said curing time ranges from 5 seconds to 30 minutes.2. The kit of claim 1 , wherein said carbodiimide in said sub-formulation B is dissolved in water.3. The kit of claim 1 , wherein said matrix is characterized by at least one of:a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; anda biodegradability ...

Подробнее
Номер записи: 84
17-05-2018 дата публикации

Biopolymer System for Tissue Sealing

Номер: US20180133363A1
Автор: Abrahams John M., Chen Weiliam
Принадлежит:

A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug. 1. A tissue sealant for sealing a biological tissue of a living mammal , the sealant comprising a hydrogel , the hydrogel being formed by gelation of a premix , the premix comprising an alkylated chitosan or a gelatin , and a polybasic carboxylic acid or an oxidized polysaccharide , in an aqueous medium.2. (canceled)3. The tissue sealant of wherein the hydrogel is adapted to adhere to biological tissue of a living mammal claim 1 , to adhesively seal the tissue.4. The tissue sealant of wherein the alkylated chitosan comprises poly(oxyalkylene)chitosan claim 1 , the poly(oxyalkylene)chitosan preferably comprising poly(oxyethylene)chitosan.5. The tissue sealant of wherein the alkylated chitosan comprises acrylated chitosan.6. The tissue sealant of wherein the polybasic carboxylic acid comprises an acidic polysaccharide claim 1 , the acidic polysaccharide preferably comprising a hyaluronan or a carboxymethylcellulose.78.-. (canceled)9. The tissue sealant of wherein the oxidized polysaccharide comprises oxidized dextran claim 1 , oxidized starch claim 1 , or oxidized hyaluronan.1011.-. (canceled)12. The tissue sealant of wherein the living mammal is a living human being.1314.-. (canceled)15. The tissue sealant of further comprising a therapeutic or protective agent.1620 ...

Подробнее
Номер записи: 85
07-08-2014 дата публикации

Device For Promotion Of Hemostasis And/or Wound Healing

Номер: US20140220130A1
Автор: Kristian Larsen, Mads Sabra
Принадлежит: Ferrosan Medical Devices AS

The present invention relates to a matrix material comprising a pharmaceutical composition such as a matrix material with a pharmaceutical composition printed on the surface. In one embodiment the pharmaceutical composition comprises thrombin. The invention further describes a method for making the matrix material with a pharmaceutical composition printed on the surface. In one specific embodiment the invention also relates to the use of said matrix material for promotion of hemostasis and/or wound healing. The invention also relates to a kit-of-parts comprising a matrix with a pharmaceutical composition and a container with a peelable lid.

Подробнее
Номер записи: 86
09-05-2019 дата публикации

METHODS AND COMPOSITIONS FOR TISSUE ADHESIVES

Номер: US20190133685A1
Автор: Huang Huang-Chiao, Rege Kaushal
Принадлежит:

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue. 134.-. (canceled)35. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof.36. The bioadhesive composition of claim 35 , wherein the light absorbing chromophore comprises silver nanoparticles claim 35 , gold nanorods claim 35 , or gold nanoparticles claim 35 , or mixtures thereof.37. The bioadhesive composition of claim 35 , wherein the bioadhesive composition further comprises an active agent claim 35 , cells claim 35 , or a combination thereof.38. The bioadhesive composition of claim 37 , wherein the active agent comprises an antibacterial agent.39. The bioadhesive composition of claim 37 , wherein the active agent comprises an MMP inhibitor claim 37 , a soluble factor claim 37 , a cytokine claim 37 , or a growth factor.40. The bioadhesive composition of claim 39 , wherein the soluble factor comprises FGF (fibroblast growth factor) claim 39 , TGF-beta claim 39 , EGF or other factors known as growth factors or cytokines claim 39 , or known to be involved in wound healing and repair.41. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof,wherein the light absorbing chromophore is configured to convert light to heat upon the application of an effective amount of a directed light beam to the bioadhesive composition, ...

Подробнее
Номер записи: 87
09-05-2019 дата публикации

SHEET-LIKE HEMOSTATIC MATERIAL EMPLOYING POLY-GAMMA-GLUTAMIC ACID, AND METHOD OF MANUFACTURING SAME

Номер: US20190134260A1
Автор: Matsuda Kazuhisa, Nakamura Yusuke, Sugahara Yoshikatsu
Принадлежит:

A sheet-like hemostatic material is provided with: an adhesive layer which serves as an affixing surface to a bleeding site and which is formed from at least poly-γ-glutamic acid (γ-PGA); and a covering layer which is a sheet formed from at least one biodegradable material (covering material) other than γ-PGA, and which serves as an opposite surface to the affixing surface. At least one of the adhesive layer and the covering layer is a single sheet. If the adhesive layer is a single sheet, the adhesive layer should be a sponge-like sheet, and if the adhesive layer is a partial layer, the adhesive layer should be a sponge-like sheet or a nonporous layer. Alternatively, in another sheet-like hemostatic material, a sheet which is formed from at least poly-γ-glutamic acid (γ-PGA) and to which at least one of a saccharide and collagen has been added is provided as the adhesive layer. 1. A sheet-like hemostatic material provided with an adhesive layer which serves as an affixing surface to a bleeding site and which is formed from at least poly-γ-glutamic acid.2. The sheet-like hemostatic material according to claim 1 , further comprising a covering layer which is provided on an opposite surface of the affixing surface and is formed from at least one biodegradable material other than the poly-γ-glutamic acid claim 1 , wherein at least one of the adhesive layer and the covering layer is a single sheet.3. The sheet-like hemostatic material according to claim 2 , wherein the adhesive layer is a sponge-like sheet when the adhesive layer is the single sheet.4. The sheet-like hemostatic material according to claim 2 , wherein when the adhesive layer is a partial layer which is not the single sheet claim 2 , the adhesive layer is a sponge-like sheet formed from at least poly-γ-glutamic acid or a nonporous layer.5. The sheet-like hemostatic material according to claim 2 , wherein the covering layer is a sponge-like sheet formed from at least a crosslinked collagen.6. The sheet- ...

Подробнее
Номер записи: 88
09-05-2019 дата публикации

PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOOD

Номер: US20190134261A1
Автор: Bouler Jean-Michel, Bujoli Bruno, Gauthier Olivier, Janvier Pascal, Mellier Charlotte
Принадлежит:

A bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed. 1. A bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm , and a liquid component comprising blood.2. The bone cement paste of claim 1 , wherein the liquid component is blood.3. The bone cement paste of claim 1 , wherein the powder component further comprises at least one calcium phosphate compound other than α-TCP.4. The bone cement paste of claim 3 , wherein the calcium phosphate compound is selected from the group consisting of hydroxyapatite (HA) claim 3 , amorphous calcium phosphate (ACP) claim 3 , monocalcium phosphate anhydrous (MCPA) claim 3 , monocalcium phosphate monohydrate (MCPM) claim 3 , dicalcium phosphate dihydrate (DCPD) claim 3 , dicalcium phosphate anhydrous (DCPA) claim 3 , precipitated or calcium-deficient apatite (CDA) claim 3 , β-tricalcium phosphate (β-TCP) claim 3 , tetracalcium phosphate (TTCP) claim 3 , and mixtures thereof.5. The bone cement paste of any one of claim 1 , wherein the powder component comprises:α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, andat least one calcium phosphate compound selected from the group consisting of: MCPM, DCPD, CDA, and mixtures thereof.6. The bone cement paste of claim 1 , wherein the powder component comprises at least 70% by weight of α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm claim 1 , in relation to the total weight of said powder component.7. The bone cement paste of claim 1 , wherein the powder component comprises:α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μmMCPM, ...

Подробнее
Номер записи: 89
04-06-2015 дата публикации

FUNCTIONALIZED SURGICAL ADHESIVES

Номер: US20150151019A1
Автор: Ladet Sébastien
Принадлежит:

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition. 145-. (canceled)46. A bioadherent composition which comprises:a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a first ligand capable of binding a first receptor on biological tissue; anda second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a second ligand capable of binding a second receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.47. The bioadherent composition according to wherein the members of the specific binding pair bind to one another via a Huisgen cycloaddition reaction claim 46 , a Diels-Alder reaction and a thiol-ene reaction.48. The bioadherent composition according to wherein the members of the specific binding pair are alkynes and azides.49. The bioadherent composition according to wherein the reactive member is an alkyne and the complementary reactive member is an azide.50. The bioadherent composition according to wherein the reactive members ...

Подробнее
Номер записи: 90
01-06-2017 дата публикации

JOINING AND/OR SEALING TISSUES THROUGH PHOTO-ACTIVATED CROSS-LINKING OF MATRIX PROTEINS

Номер: US20170151366A1
Автор: Brownlee Alan George, Elvin Christopher Malcolm
Принадлежит:

A method of joining and/or sealing tissues in a surgical procedure or medical treatment, comprising the steps of: (1) applying a matrix protein, a photoactivatable metal-ligand complex and an electron acceptor to a tissue portion; (2) irradiating said tissue portion to photoactivate the photoactivatable metal-ligand complex; thereby initiating a cross-linking reaction of the matrix protein to seal said tissue portion or join said tissue portion to an adjacent tissue portion. 2. A method as claimed in wherein the matrix protein is selected from the group consisting of fibrinogen claim 1 , fibrin claim 1 , collagen claim 1 , fibronectin claim 1 , keratin and laminin claim 1 , or admixtures thereof.3. A method as claimed in wherein the matrix protein is selected from the group consisting of fibrinogen claim 2 , fibrin claim 2 , collagen and fibronectin claim 2 , or admixtures thereof.4. A method as claimed in wherein the matrix protein is fibrinogen.5. A method as claimed in wherein the photoactivatable metal-ligand is an Ru(II) claim 1 , Pd(II) claim 1 , Cu(II) claim 1 , Ni(II) claim 1 , Mn(II) or Fe(III) complex.6. A method as claimed in wherein the complex is an Ru(II) bipyridyl complex claim 5 , a Pd(II) porphyrin complex claim 5 , a sulfonatophenyl Mn(II) complex or a Fe(III) protoporphyrin complex.7. A method as claimed in wherein the complex is a tris(bipyridyl) Ru(II) complex.8. A method as claimed in wherein the complex is tris(bipyridyl) Ru(II) dichloride.9. A method as claimed in wherein the electron acceptor is a persulfate claim 1 , periodate claim 1 , perbromate or a perchlorate compound.10. A method as claimed in wherein the electron acceptor is a persulfate compound.11. A method as claimed in wherein the electron acceptor is ammonium persulfate or sodium persulfate.12. A method as claimed in wherein a blood vessel is sealed to prevent blood loss.13. A method as claimed in wherein a cut surface of an organ is sealed.14. A method as claimed in wherein ...

Подробнее
Номер записи: 91
21-08-2014 дата публикации

Composite Collagen Sponge and Preparation Method Thereof

Номер: US20140235539A1
Автор: WANG Shanshan
Принадлежит:

The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times. The preparation method includes a cation chromatographic purification step and a two-stage inactivation step consisting of organic solvent/detergent virus inactivation and dry heat virus inactivation. The composite collagen sponge obtained by the method of the present invention not only improves the safety and performance of the product in clinical applications, but also ensures the stability and the bioactivity throughout the effective life of the product. 1. A composite collagen sponge comprising collagen and at least one cell growth factor , the composite collagen sponge having a water absorption capacity of more than 52 times the weight of the composite collagen sponge absorbing water.2. The composite collagen sponge according to claim 1 , having an elastic modulus of more than 70.0 N/cm.3. The composite collagen sponge according to claim 2 , further comprising a protecting agent comprising at least one amino acid claim 2 , at least one saccharide claim 2 , and an albumin in a weight ratio of (1 to 11):(1.25 to 17.5):(1 to 7.5).4. (canceled)5. The composite collagen sponge according to claim 3 , wherein the protecting agent further comprises glycerol.6. (canceled)7. A method for preparing the composite collagen sponge according to claim 1 , the method comprises:forming a collagen solution,purifying the collagen solution using ion exchange chromatograph with an eluent comprising, sodium chloride at a concentration of from 0.2 mol/L to 0.8 mol/L and sodium acetate at a concentration of 0.1 mol/L, wherein the ion exchange chromatogrpahy is a preparative chromatography with CM52 cation exchange resins, and wherein the eluent has a pH of 4.5.8. The method for preparing the composite collagen sponge according to claim 7 , ...

Подробнее
Номер записи: 92
21-08-2014 дата публикации

BIOCOMPATIBLE PHASE INVERTIBLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

Номер: US20140235825A1
Автор: Dieck Ronald, Handley Ian J., Winterbottom Neil, Wong Joanna
Принадлежит: Tenaxis Medical, Inc.

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. 1. A method of producing a phase invertible composition , said method comprising: (a) a liquid proteinaceous substrate; and', '(b) a liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and a glycosaminoglycan, wherein the liquid crosslinking composition has been formed prior to combining with the liquid proteinaceous substrate to produce said phase invertible composition;, 'combining;'}wherein said phase invertible composition is exposed to radiation.2. The method according to claim 1 , wherein the radiation sterilizes the phase invertible composition.3. The method according to claim 1 , wherein the radiation is gamma radiation.4. The method according to claim 1 , wherein the radiation is electron beam radiation.5. The method according to claim 1 , wherein said glycosaminoglycan is hyaluronan.6. The method according to claim 1 , wherein said proteinaceous substrate comprises a proteinaceous material selected from the group consisting of: albumin claim 1 , elastin claim 1 , fibrin and soluble and insoluble forms of collagen and combinations thereof.7. The method according to claim 6 , wherein said crosslinking agent comprises glutaraldehyde.8. The method according to claim 7 , wherein said glutaraldehyde is heat stabilized. This application is a continuation of U.S. patent application Ser. No. 14/055,712 (Attorney Docket No. 30908-703.302 ...

Подробнее
Номер записи: 93
08-06-2017 дата публикации

IN SITU SOLIDIFYING COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF

Номер: US20170157285A1
Автор: Stewart Russell J.
Принадлежит: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications. 1. A method for producing an adhesive solid or gel in a subject in situ comprising introducing into the subject a fluid complex coacervate comprising at least one polycation , at least one polyanion , and a monovalent salt , wherein the concentration of the monovalent salt in the complex coacervate is greater than the concentration of the monovalent salt in the subject , wherein upon introduction of the fluid complex coacervate into the subject the adhesive solid or gel is produced in situ.2. The method of for reducing or inhibiting blood flow in a blood vessel of the subject comprising introducing into the vessel the fluid complex coacervate claim 1 , wherein the adhesive solid or gel produced from the fluid complex coacervate creates an artificial embolus within the vessel.3. The method of claim 2 , wherein the method reduces or inhibits blood flow to a tumor claim 2 , an aneurysm claim 2 , a varicose vein claim 2 , an arteriovenous malformation claim 2 , or a bleeding wound.4. The method of claim 2 , wherein the fluid complex coacervate further comprises an embolic agent comprising ...

Подробнее
Номер записи: 94
24-06-2021 дата публикации

Collagen Biomaterials And Methods For Manufacturing Collagen Biomaterials

Номер: US20210187156A1
Автор: Barrett David James, Best Serena Michelle, Cameron Ruth Elizabeth, Linley Matthew
Принадлежит:

This invention relates to collagen biomaterials and methods for manufacturing collagen biomaterials. Method disclosed herein include steps of providing a suspension of insoluble collagen fibres, providing a layer deposition interface and applying an electric field across the suspension to cause electrophoretic deposition of the insoluble collagen fibres at the layer deposition interface. Biomaterials disclosed herein include a layer comprising an array of fibres of collagen, and a layered composite material comprising at least first and second fibrous layers each comprising an array of fibres of collagen, and a shape adapting layer sandwiched between the first and second fibrous layers. Biomaterials as described herein may be useful in a range of tissue engineering and other applications. 1. A layer of collagen comprising an array of fibres of collagen , the layer having a thickness direction perpendicular to a plane extending within the layer , there being defined a range of in-plane directions perpendicular to the thickness direction and lying in the plane extending within the layer ,wherein the fibres of collagen are substantially aligned within the layer along a first in-plane direction such that, when the ultimate tensile strength (UTS) of the layer is tested along said range of in-plane directions, the first in-plane direction corresponds to a maximum UTS and in a second in-plane direction, not parallel to the first in-plane direction, corresponds to a UTS that is at most 90% of the maximum UTS.2. A layer according to wherein the second in-plane direction is substantially perpendicular to the first in-plane direction.3. A layer of collagen comprising an array of fibres of collagen claim 1 , the layer having a thickness direction perpendicular to a plane extending within the layer claim 1 , there being defined a range of in-plane directions perpendicular to the thickness direction and lying in the plane extending within the layer claim 1 ,wherein the fibres of ...

Подробнее
Номер записи: 95
16-06-2016 дата публикации

BIOADHESIVE FOR OCCLUDING VESSELS

Номер: US20160166728A1
Автор: Girdhar Gaurav
Принадлежит:

Bioadhesives and crosslinked gels therefrom are disclosed. The bioadhesives can be applied to a vessel for occluding the vessel. The present disclosure also describes kits that comprise the various components for preparing and applying the bioadhesives. Bioadhesives of the present disclosure include: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier. 1. A bioadhesive comprising: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier , wherein the biopolymer and crosslinker form a crosslinked network and the biocompatible rheological modifier does not substantially react with the biopolymer or the biocompatible crosslinker.2. The bioadhesive of claim 1 , wherein the biopolymer is a protein or a polysaccharide having one or more primary amines as the first chemically reactive groups.3. The bioadhesive according to wherein the biopolymer is albumin.4. The bioadhesive according to claim 1 , wherein the biocompatible crosslinker is a multi-arm polyethylene glycol (PEG) having at least two or more N-hydroxysuccinimide (NHS) ester groups as the second chemically reactive groups.5. The bioadhesive according to claim 1 , wherein the biocompatible rheological modifier is hyaluronic acid or a salt thereof.6. The bioadhesive according to claim 1 , wherein the biocompatible rheological modifier is a shear thinning fluid with a non-sheared viscosity between 0.5 Pa·s and 200 Pa·s.7. The bioadhesive according to claim 1 , wherein the biopolymer is an albumin having ...

Подробнее
Номер записи: 96
15-06-2017 дата публикации

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

Номер: US20170165404A1
Автор: Ji Xin, Shi Xueshen, Xing Cheng
Принадлежит:

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 153-. (canceled)54. An anti-adhesion product in the form of a film , plaster , or sponge , said product comprising a biocompatible modified starch , wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units contained in the starch , wherein the product forms an adhesion barrier in the form of a starch-blood coagulation matrix upon contacting a wound tissue.55. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch particles exhibit a water absorbency capacity that is at least 1 times its own weight.56. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch particles exhibit a water absorbency capacity that is 2-500 times its own weight.57. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch exhibits a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C.58. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch is degradable by amylase.59. The anti-adhesion product of claim 54 , wherein the ...

Подробнее
Номер записи: 97
25-06-2015 дата публикации

One component fibrin glue comprising zymogens

Номер: US20150174215A1
Автор: Anne Gorman, Ashley Deanglis, Israel Nur, SIVAN DORON, Yair Pilpel, Yuri ZHERDEV
Принадлежит: Ethicon Inc, Omrix Biopharmaceuticals Ltd

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Подробнее
Номер записи: 98
25-06-2015 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20150174289A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 1. A liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide or other reversible fibrin polymerization blocking agent; wherein the blocking agent or GPRP is present in the formulation in an amount which is greater than 100 fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.2. The formulation of claim 1 , wherein the GPRP peptide is present in an amount greater than about 340 fold molar excess relative to the fibrin monomers.3. The formulation of claim 1 , wherein the GPRP peptide is present in an amount of about 340 to 460 fold molar excess relative to the fibrin monomers.4. The formulation of claim 1 , wherein the formulation is substantially free of added thrombin.5. The formulation of claim 1 , further comprising thrombin-activated Factor XIII.6. The formulation of claim 1 , further comprising a calcium chelator.7. The formulation of claim 6 , wherein the calcium chelator is a citrate ion.8. The formulation of claim 7 , wherein the citrate ion is provided by sodium citrate.9. The formulation of claim 8 , comprising from about 1 mM to about 50 mM sodium citrate.10. The formulation of claim 1 , wherein the formulation has a neutral pH.11. The formulation of claim 1 , for use in hemostasis claim 1 , sealing claim 1 , healing and/or in surgery.12. A container comprising the formulation of .13. A kit comprising the container of claim 12 , and optionally instructions for use.14. A method for preparing a sealant at a surface comprising providing the formulation of ; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at ...

Подробнее
Номер записи: 99
21-06-2018 дата публикации

Film, manufacturing method thereof, and use thereof

Номер: US20180169295A1
Автор: Kun-Mao KUO, Li-Jie LIN, Ming-Chia Yang, Tai-Horng Young, Wei-Hong Chang, Yun-Han LIN
Принадлежит: Industrial Technology Research Institute ITRI

The present disclosure provides a film composed of a polymer mixture, wherein the polymer mixture includes: a hydrophobic composition including polycaprolactone (PCL); and at least one hydrophilic polymer selected from a group consisting of: alginate, gelatin, chitosan, hyaluronic acid, collagen, demineralized bone matrix (DSM), carboxymethyl cellulose (CMC), fibrin, polyoxyethylene, polyethylene glycol (PEG) and polyvinylpyrrolidone, wherein the weight ratio of the hydrophobic composition to the at least one hydrophilic polymer is about 1:0.01-100, and wherein the film has the effect of preventing leakage from a surgical wound or a diffuse wound.

Подробнее
Номер записи: 100